

XtalPi


晶泰科技

XtalPi Holdings Limited

晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 2228



2025

INTERIM REPORT

Contents

Corporate Information	2
Financial Summary	4
Corporate Profile	5
Management Discussion and Analysis	14
Corporate Governance and Other Information	23
Report on Review of Interim Financial Information	32
Condensed Consolidated Statement of Profit or Loss	33
Condensed Consolidated Statement of Comprehensive Income	34
Condensed Consolidated Balance Sheet	35
Condensed Consolidated Statement of Changes in Equity	37
Condensed Consolidated Statement of Cash Flows	39
Notes to Interim Financial Information	40
Definitions	68

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Dr. Wen Shuhao (*Chairman*)
Dr. Ma Jian (*Chief Executive Officer*)
Dr. Lai Lipeng
Dr. Jiang Yide Alan

Independent Non-executive Directors

Mr. Law Cheuk Kin Stephen
Ms. Chan Wing Ki
Mr. Chow Ming Sang

AUTHORISED REPRESENTATIVES

Dr. Wen Shuhao
Ms. Liu Shimei

AUDIT COMMITTEE

Mr. Law Cheuk Kin Stephen (*Chairman*)
Ms. Chan Wing Ki
Mr. Chow Ming Sang

REMUNERATION COMMITTEE

Mr. Law Cheuk Kin Stephen (*Chairman*)
Dr. Ma Jian
Mr. Chow Ming Sang

NOMINATION COMMITTEE

Dr. Wen Shuhao (*Chairman*)
Mr. Law Cheuk Kin Stephen
Ms. Chan Wing Ki

JOINT COMPANY SECRETARIES

Ms. Liu Shimei
Ms. Chan Sau Ling

LEGAL ADVISORS

As to Hong Kong laws

Sidley Austin

39/F, Two International Finance Centre
8 Finance Street
Central
Hong Kong

AUDITOR

PricewaterhouseCoopers

*Certified Public Accountants and
Registered Public Interest Entity Auditor*
22/F, Prince's Building
Central
Hong Kong

COMPLIANCE ADVISOR

UOB Kay Hian (Hong Kong) Limited

6/F, Harcourt House
39 Gloucester Road
Hong Kong

REGISTERED OFFICE

PO Box 309
Ugland House
Grand Cayman
KY1-1104
Cayman Islands

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

3/F, Second Phase of the International
Biomedical Industrial Park
No. 2 Hongliu Road
Futian District
Shenzhen
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1917, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited

PO Box 1093
Boundary Hall
Cricket Square
Grand Cayman KY1-1102
Cayman Islands

HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited

17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

STOCK CODE

The Company's shares are listed on the Main Board of
The Stock Exchange of Hong Kong Limited

Stock code: 2228

COMPANY WEBSITE

www.xtalpi.com

Financial Summary

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue	517,076	102,630
Research and development expenses	(221,527)	(210,390)
Profit/(loss) for the period	75,609	(1,237,550)
Adjusted net profit/(loss) (non-IFRS measure)*	141,628	(251,396)

* Adjusted net profit/(loss) is not defined under the IFRS. It represents the profit/(loss) for the period adjusted by adding back (i) changes in fair value of CRPS, (ii) share-based compensation expenses, and (iii) listing expenses.

We are a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform. We adopt a combination of quantum physics-based first-principles calculation¹, AI, high performance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&D solutions and services to global and domestic companies in the pharmaceutical and material science (including agritech, energy and new chemicals, and cosmetics) industries and beyond.

We have a diverse customer base, ranging from start-ups to global biotechnology and pharmaceutical companies, as well as unicorns and leading companies in the field of new materials. Our customer base includes 17 of the top 20 global biotechnology and pharmaceutical companies, which we believe is an indicator of the caliber of our solutions and services. With operations in both China and the U.S., we strive to take advantage of the best capabilities and resources available to us in each region to meet the evolving needs of our customers and collaborators and academic partners. We have well-established and longstanding relationship with many of the world's leading biotechnology and pharmaceutical conglomerates and leading companies in the field of new materials, such as Pfizer Inc., Johnson & Johnson, Merck KGaA, Darmstadt, Germany, and Sinopec Shanghai Research Institute many of which are our repeat customers.

VISION

Our vision is becoming the global leader in quantum physics-based, AI-powered drug and material science R&D.

MISSION

Our mission is a world of smarter science, better lives. We aim to accelerate the design and discovery of novel drugs and materials leveraging quantum physics², AI and robotic automation.

BUSINESS OVERVIEW AND PROSPECTS

1. Overall Performance

We are pleased to report our financial results for the first half of 2025, highlighted by revenue of RMB517.1 million, with a year-on-year growth of 403.8%. We ended the Reporting Period with a healthy Cash Balance³ of RMB5,307.7 million, and average monthly cash burn decreased by 20.0% to RMB49.7 million. We also achieved profitability for the first time on a half-year basis with adjusted net profit of RMB141.6 million. This milestone is a testament to our collective effort and innovation, signaling our entry into a new phase of large-scale growth and strengthening the foundation for our long-term strategy.

Furthermore, during the Reporting Period, the Company was included in the MSCI China Small Cap Index, an authoritative recognition of our investment value by the international capital markets.

¹ Quantum physics is the study of matter and energy at the most fundamental level, aiming to uncover the properties and behaviors of the very building blocks of nature. First-principles calculation is a method to calculate physical properties directly from basic physical quantities, such as the mass and charge, and the electrostatic force of an electron, based on the principle of quantum mechanics.

² Our business does not involve quantum computing or the use of quantum computers, nor is quantum computing or the use of quantum computers a primary mode of our operations.

³ Cash Balance comprising our cash and cash equivalents, term deposits, the current portion of financial assets at fair value through profit or loss, and restricted cash as of 30 June 2025.

Corporate Profile

2. Business Development Progress

2.1 Drug Discovery Solutions: The Deep Integration of Advanced AI and Robotics Driving New Growth for Our Business

During the Reporting Period, revenue from the drug discovery solutions business recorded exceptionally strong growth, surging 615.2% from RMB60.9 million for the six months ended 30 June 2024 to RMB435.2 million for the six months ended 30 June 2025. This increase was primarily driven by the execution of the Group's major collaboration with DoveTree Medicines LLC and its affiliates ("**DoveTree**"). We achieved the first-phase milestone of this collaboration and received an initial payment of US\$51 million. Additionally, revenue from our antibody business also showed significant improvement.

(1) **AI + Robotics Drug Discovery Platform Gains Global Recognition, Ushering in a New Era of Business Growth.** In late June 2025, we entered into a landmark collaboration with DoveTree, a company founded by Professor Gregory Verdine, a renowned leader in biopharmaceuticals. The agreement provides for an initial payment of US\$51.0 million for the first phase, with an additional US\$49.0 million in potential payments, and variable payments of up to US\$5.89 billion subject to regulatory and commercial milestones, along with potential royalties based on a single-digit percentage of the annual net sales of the products. Through this collaboration, our proprietary AI + robotics drug discovery platform will support Professor Verdine's DoveTree in developing small-molecule and antibody drugs across multiple therapeutic areas, including oncology, immunologic and inflammatory diseases, neurological disorders and metabolic dysregulation. DoveTree will obtain exclusive development and commercialization rights for the above products worldwide. During the the six months ended 30 June 2025, we achieved the first-phase milestone and recognised US\$51 million as revenue. In addition, we plan to appoint Professor Verdine as an advisor, where he will guide pipeline candidate selection and provide early assessments of clinical success potential. Backed by our clients' strong recognition of our platform's capabilities, our drug discovery business has already successfully developed multiple pipelines, securing substantial initial payments and locking in potential future milestone and royalty revenues. These milestones signal the start of a new growth chapter for our drug discovery business.

(2) Breakthrough Progress Across Multiple Pipelines

- **All three of our projects in collaboration with a leading biopharmaceutical company have successfully reached key milestones.** Notably, a chronic disease project launched in 2024 achieved its PCC milestone a full quarter ahead of schedule, highlighting the outstanding capabilities of XtalPi's fully integrated AI-computational-experimental platform in accelerating drug discovery. Building on this momentum, our partner has initiated a new round of collaborations with us this year, focusing on additional novel drug targets and indications.
- **Empowered the development of the world's first AI-designed brain-penetrant PRMT5 inhibitor, advancing it to the IND stage.** In close collaboration with PharmaEngine, Inc., we successfully developed PE-0260, a breakthrough PRMT5 inhibitor with strong therapeutic potential. Leveraging AI-driven rational drug design and computational chemistry, our teams explored a broader chemical space and identified the preclinical candidate PE-0260 through an AI-assisted molecular evaluation system. PharmaEngine has now completed filing its IND application and initiated clinical trials.

- **A drug we co-developed with our incubated company Signet Therapeutics — the world’s first targeted treatment for diffuse gastric cancer — has been nominated for the Prix Galien Award for Best Biotechnology Product, often hailed as the “Nobel Prize of the pharmaceutical industry.” This treatment is the only pipeline from Asia to earn a nomination this year, and just the fourth from a Chinese company in the award’s 50-plus-year history.**
This first-in-class candidate, also the first AI-and organoid-enabled therapy for diffuse gastric cancer to enter clinical trials worldwide, was developed using XtalPi’s AI + robotics platform for molecular discovery and design. Powered by XtalPi’s cutting-edge technologies, this program advanced from initiation to the identification of preclinical candidates in just over six months. During the research, XtalPi also applied its proprietary Xpose technology to predict the binding patterns of potential targets and used XFEP to estimate the affinity between molecules and targets, leading to the successful identification and experimental validation of a novel target, SRC. This discovery demonstrated for the first time that dual inhibition of FAK and SRC produces a synergistic effect superior to inhibiting either target alone. The program is progressing smoothly in Phase I clinical trials, with all patients in the fourth dose cohort enrolled for safety evaluation. This drug has been granted FDA Orphan Drug Designation for gastric cancer and, in February 2025, received FDA Fast Track Designation. In July 2025, STAT, a leading global health and life sciences publication, highlighted the program in its “First Opinion” column as a prime example of China’s growing impact on global drug innovation.
- **Antibody business achieves rapid commercial growth.** Driven by our high-quality delivery of previously placed orders, revenue in the first half of 2025 soared, reaching nearly two times the total revenue of 2024. We have also deepened collaborations with several globally renowned pharmaceutical companies, evolving from a service provider into a platform-based co-developer, significantly increasing the lifetime value of each customer. During the Reporting Period, our antibody R&D platform also made important technical breakthroughs. XtalFold®, developed by XtalPi in 2023 and continuously upgraded, launched its new Ultra mode, greatly enhancing performance in modeling complex biomacromolecules. XtalFold® has delivered strong results across multiple applications, including antigen design, epitope mapping, affinity maturation, pH sensitivity optimization, and bispecific antibody design. In rigorous benchmark tests, it demonstrated industry-leading performance in both overall success rate and modeling quality in challenging areas such as antibody–antigen interfaces. The platform has already been successfully licensed to multiple multinational pharmaceutical companies.
- **XtalPi AI drives key advances for two pipelines of incubated company Leman Biotech.** (1) Leman’s metabolically enhanced CD19 CAR-T therapy has successfully treated multiple patients with systemic lupus erythematosus (SLE). The therapy required only one-thousandth of the standard dose used in conventional CD19 CAR-T treatments and eliminated the need for lymphodepletion pretreatment, dramatically reducing side effects. After treatment, patients were able to discontinue all medications and were clinically confirmed to have achieved DORIS remission, that is, complete remission without medication. (2) **Leman Biotech also accelerated preparation for its solid tumor CAR-T investigator-initiated trial (IIT).** By combining AI algorithms with high-throughput experiments, we optimized a key metabolic enhancer, significantly improving receptor binding affinity and immune activity, enabling the project to advance into IIT preparation in the first half of 2025.

(3) Enhancing AI Capabilities to Create a Drug Discovery Superintelligence

- **Strengthening our Pfizer partnership while continuously improving AI-driven drug discovery models**

We have developed over 200 AI models covering molecular generation, free energy perturbation, property prediction, and crystal structure prediction. For the six months ended 30 June 2025, building on our earlier strategic partnership with Pfizer, we continued to iterate and optimize these models while deepening our collaboration to co-develop a next-generation, AI-driven molecular simulation platform. This collaboration focuses on constructing new classical mechanics-based models tailored to Pfizer's unique chemical space and deploying Pfizer's localized XFEP free energy perturbation platform, covering the entire workflow from parameter customization to FEP calculations. Additionally, we are actively expanding the platform's capabilities across diverse applications, including small molecules, peptides, and antibodies, to comprehensively empower Pfizer's drug discovery efforts.

- **AI-driven antibody platform XtalFold® continues to undergo iterative upgrades**

During the Reporting Period, our AI antibody development platform XtalFold® launched a new Ultra mode. Compared with Normal mode, Ultra mode improves accuracy by approximately 10 percentage points in antigen-antibody complex structure prediction, significantly enhancing its performance in modeling complex biomolecules. In July, our self-developed AI antibody drug structure modeling platform XtalFold® was honored as one of the "Top 10 AI Innovations (Technologies/Products)" at the World Artificial Intelligence Conference (WAIC). The platform was presented in a high-profile event at the conference, showcasing our Company's leading strength in AI-driven biopharmaceutical technology.

- **Emerging Modality: Molecular Glue Platform**

During the Reporting Period, we officially launched the development of our Molecular Glue platform, focusing on the DMTA (Design — Make — Test — Analyze) closed-loop framework in new drug development. We are actively building a digital management system that integrates all modules seamlessly. Our core Molecular Glue team is now in place and has established initial collaboration with key opinion leaders from both industry and academia. Meanwhile, the team is conducting in-depth discussions with multiple pharmaceutical companies on specific targets and screening strategies. Initial feedback has been positive, and partnership intentions are steadily progressing.

On computational modeling, our team continues to optimize our quantum physics-based XFEP algorithm and has developed new algorithmic models for molecular glues' structure-activity relationships, capable of affinity and activity predictions. These models are currently undergoing iterations and improvements. Additionally, by integrating protein surface fingerprinting with structure-sequence-driven PPI mining algorithms, the team has successfully identified around 1,000 potential molecular glue targets using the representative E3 ligase cereblon (CRBN). This effort also led to the creation of a virtual molecular glue library containing over 1.1 million molecules.

On the experimental side, the platform has established a range of biological assays tailored for molecular glue screening. Leveraging the Company's in-house cryo-EM capabilities, our team successfully resolved ternary complex structures at industry-leading resolution, providing critical structural insights for subsequent molecular optimization. Currently, screening for CRBN-dependent molecular glues is in full swing, with initial active hit molecules identified for two target proteins.

- **Emerging Modality — Peptide and Protein R&D Platform PepiX™**

During the Reporting Period, we launched PepiX™, a world-leading peptide and protein R&D platform that deeply integrates generative AI molecular design, automated synthesis, trillion-scale peptide library construction, and high-throughput screening. Through an iterative “AI-driven design–synthesis–validation” cycle, PepiX™ delivers high efficiency, precision, and success rates in peptide and protein drug development. The platform now supports early-stage peptide drug research, functional peptide product development, and discovery of new active cosmetic ingredients, achieving notable results across multiple fields.

- 0 In AI-driven cancer vaccine development, candidate molecules designed by the platform have demonstrated strong immunogenicity in preclinical animal models and are poised to enter clinical trials.
- 0 Two independently developed oral peptide health products for blood sugar regulation and fat reduction have completed efficacy and toxicology evaluations and are now entering the regulatory approval process.
- 0 In collaboration with the National Cancer Centre Singapore (NCCS), a renal cancer FIC target development project leveraged the platform's cyclic peptide design and high-throughput screening capabilities to rapidly achieve key milestones and has advanced to downstream efficacy validation.

Additionally, to differentiate the platform, we have successfully established a library of over 2,000 non-natural amino acid monomers. These monomers offer advantages such as ease of chemical synthesis, high structural diversity, and strong stability, with all compounds fully parameterized for computational modeling. The creation of this non-natural amino acid library significantly expands the chemical space for molecular design and exploration, effectively addressing key challenges in peptide drug development, such as poor stability, weak affinity, and low membrane permeability, from the very outset of computational design.

Corporate Profile

- **Breakthrough in mRNA2vec Technology: Pioneering a New Paradigm in mRNA Design**

At the AAAI (Association for the Advancement of Artificial Intelligence) conference, we presented our breakthrough research on mRNA2vec, pioneering a new paradigm for intelligent mRNA design. This AI-driven technology revolutionizes mRNA vaccine and drug development by optimizing sequence design, significantly enhancing expression levels and stability while addressing issues of traditional screening methods, like high costs and lengthy timelines. Leveraging mRNA2vec, we accurately identified highly efficient 5'UTR vectors that dramatically boost protein expression using only 15 candidate sequences, greatly reducing trial-and-error costs and development cycles. This innovation overcomes dual challenges, optimizing expression while maintaining stability, paving the way for personalized mRNA therapeutics and empowering cutting-edge fields such as cancer vaccines and gene therapy.

2.2 Intelligent Robotics Solutions: AI + Robotics Driving a Transformation in Chemistry

During the Reporting Period, revenue from the intelligent robotics solutions business soared 95.9%, rising from RMB41.8 million for the six months ended 30 June 2024 to RMB81.9 million for the six months ended 30 June 2025. This strong performance was driven by the rapid growth from our automated chemical synthesis services and our XtalPi R&D solutions.

(1) **AI + Robotics Reshape the R&D Paradigm, Building Vertical Superintelligence**

Leveraging AI + robotics, we have built a unique flywheel system integrating high-throughput experimentation, high-quality data, and advanced AI models, the first of its kind in the industry. Our robotics lab platform operates 24/7, continuously conducting experiments and rapidly generating vast amounts of high-quality data. This data is used to train various AI models, which are then applied across critical R&D processes, including target analysis, molecular generation, virtual screening, synthesis strategy recommendation, reaction outcome prediction, patent search, and structured knowledge management.

This system is profoundly transforming traditional R&D approaches and driving a paradigm shift in drug and materials development. We firmly believe that vertical AI4S, powered by high-quality data, will become a disruptive force in the industry.

Currently, our AI models and robotics laboratory have been widely applied across the field of chemistry, significantly expanding the accessible chemical space, overcoming critical bottlenecks in drug and new material molecule development, and effectively accelerating delivery timelines. During the Reporting Period, we also made significant progress in several key technologies:

- **The Future of Chemistry: Innovation Breakthroughs Powered by Models and Data**

In the chemical reaction stage, leveraging extensive experimental data from our robotics lab and knowledge graphs obtained via the LLM-powered literature search tool PatSight, we have successfully developed AI models for synthetic feasibility prediction and reaction condition recommendation covering common reaction types. In practice, these models have boosted the success rate of predicting chemical reactions to over 85%. As of 30 June 2025, we had accumulated 26 million chemical reaction data points through robotics experiments and LLM-driven data mining of literature. Building on this robust data foundation, our research has expanded from conventional reaction types to more challenging frontier chemistries such as photochemical reactions, continuously generating high-value next-generation reaction data and pushing the technical boundaries of the chemistry field.

In the separation and purification phase, we developed reaction condition recommendation and yield prediction models tailored for condition screening, which have been successfully applied in multiple client projects. In two of these projects, yields exceeded 50%. Additionally, we created separation algorithms optimized for high-and medium-pressure conditions, trained on 3,000 to 4,000 high-quality labeled data points. The high-pressure separation algorithm has been deployed in real client projects, delivering strong results and earning high customer praise.

Additionally, we have completed the acquisition of Liverpool ChiroChem (LCC), a company with deep expertise in chiral chemistry, strengthening our capabilities in chemical space exploration. LCC boasts a world-leading library of chiral molecules and a high-quality database, offering significant advantages in molecular quality and diversity and providing strong data support for AI-driven exploration of the chiral chemical space. By integrating LCC's resources and technological strengths, XtalPi will more efficiently and precisely deliver services to clients worldwide in new drug development, new material discovery, and high-value chemicals.

- **Breakthrough in Embodied Intelligence: “NeoDispenser” Solves Key Challenges in Robotic Laboratories**

In the Reporting Period, we achieved significant breakthroughs in robotic laboratories, notably advancing embodied intelligence technology. We successfully developed a new generation of modular robotic systems that integrate advanced visual perception, AI, and robotic technologies to tackle some of the most challenging problems in chemical research.

For example, our new-generation modular robot features our patented “NeoDispenser,” a flexible gripper that successfully mimics human hand operations with exceptional dexterity, earning recognition from top global clients. This design addresses three major industry pain points: (1) precise handling of trace powders: the NeoDispenser can accurately dispense solid reagents below 5 mg; (2) overcoming traditional solutions' poor adaptability to different powders: due to high variability in powder flow, viscosity, and particle size distribution, existing automated solutions cover only limited powder types and often rely heavily on manual operations. The NeoDispenser effectively resolves these adaptability issues, advancing the industry toward greater automation and intelligence; (3) eliminating intermediate containers to reduce costly material waste: the NeoDispenser draws powder directly from original reagent bottles, avoiding secondary transfers and sample preprocessing, significantly reducing loss of expensive reagents and small-volume samples.

Its core technical features include:

Advanced Visual Perception: Features cutting-edge visual perception algorithms that analyze powder characteristics in real time, enabling precise identification and handling of different powder types.

Intelligent Database: Integrates a comprehensive powder attribute database with advanced learning capabilities that continuously optimize powder handling strategies.

Powder Analysis Foundation Model: Powered by a specialized AI model trained and fine-tuned on diverse powder datasets to accurately predict powder properties and behavior.

Seamless Robot Integration: Seamlessly connects with powder packaging and other robotic systems, adjusting parameters and control strategies in real-time based on visual feedback.

Corporate Profile

- **Multi-Agent Systems Driving a Revolution in Chemistry: From Massive Chemical Space Exploration to Fully Autonomous Decision-Making**

We are progressively deploying Multi-Agent systems across the entire chemical synthesis workflow. For the Reporting Period, we successfully built a cost-effective, high-performance data platform capable of predicting synthetic feasibility across trillions of chemical compounds. Combined with Multi-Agent acceleration, this platform enables fully autonomous execution of chemical synthesis experiments. Our Multi-Agent system includes modules for procurement decision-making, automated experiment execution, reaction process control, and data management and quality assurance, all working in concert with specialized AI model tools. This system not only enables autonomous decision-making and efficient synthesis execution but also significantly boosts synthesis throughput and data accumulation, ultimately leading to the establishment of a closed-loop system for high-throughput automated synthesis data.

- **LLM-powered Drug R&D Data Extraction – PatSight Patent Mining Platform Accelerates Structure Analysis**

Our PatSight patent mining platform, jointly developed and iterated with the IDEA Research Institute, has achieved breakthrough progress powered by LLMs and deep neural network technologies. The platform can efficiently extract core data from literature and patents, such as molecular structures, activities, pharmacological effects, and reactions, with an accuracy rate of up to 97%, significantly enhancing the efficiency of structure analysis and data acquisition. PatSight overcomes the inefficiencies of traditional manual processing, providing effective public big data support for AI4S models in specialized domains. During the Reporting Period, the platform secured multiple procurement and collaboration agreements with domestic and multinational pharmaceutical companies.

- **Consistently Upgrading our Materials Research Platform and Exploring Applications Across Multiple Material Domains**

During the Reporting Period, we established a next-generation smart, automated crystallization platform that covers the entire process, from experimental design and screening execution to analysis, characterization, and report generation. This platform enables serialized, centralized, full-volume data management, significantly expanding the Company's use of digitalization and smart technology in materials research. Meanwhile, we have continued to expand our technological applications across new chemical materials, including adhesives, coatings, electrolytes, catalysts, and advanced carbon materials. We have also secured orders from several leading companies in the materials sector, with overall project progress advancing smoothly.

(2) **XtalPi R&D Solutions Achieve Global Commercial Breakthroughs**

With the continuous advancement of XtalPi's technological capabilities, our XtalPi R&D solutions have gained customer recognition and are rapidly expanding into international markets. During the Reporting Period:

- **We signed a multi-million US Dollar agreement with South Korea-based JW Pharmaceutical, one of Asia's leading pharmaceutical companies.** Under the deal, XtalPi will deliver a comprehensive solution that includes a high-throughput automated synthesis workstation, an AI-driven reaction condition optimization system, and an intelligent analysis platform. Featuring Bayesian optimization algorithms, digital experiment management, and advanced automated lab technologies, this integrated solution will significantly boost synthesis success rates and repeatability while shortening drug development cycles. The collaboration will provide JW with a robust technological foundation to accelerate breakthrough pipeline development in oncology, metabolic diseases, and other key areas, fast-tracking more globally competitive drug candidates into clinical trials.

- **We signed a multi-million US Dollar cooperation agreement with Liangzhu Laboratory**, established by Zhejiang University in July 2020. Specializing in tissue degeneration and gene mutation diseases, Liangzhu serves as a strategic scientific bridge between academia and the life sciences industry. Under this partnership, XtalPi and Liangzhu will collaborate on setting up a robotics-powered biomaterials laboratory, with XtalPi providing a smart robotics platform spanning their entire workflow from synthesis to testing.
- **We entered into a key partnership with Roche**, under which XtalPi will integrate robotics, transport and barcode scanning modules, stacker cranes, and automated pallet and tube handling systems to enable automated sorting, high-throughput storage, and precise retrieval of molecular building blocks. Users can customize their experimental workflows through a flexible software interface. Moreover, the system's smart algorithms handle autonomous storage allocation, intelligent shortage alerts, and retrieval notifications based on building block usage frequency, greatly enhancing automation in experiment material management and improving overall laboratory efficiency.

3. Prospects and Outlook

We believe the future of scientific discovery lies in the seamless fusion of artificial intelligence, embodied intelligence, and human insight. We are boldly tackling challenges to unlock new frontiers, transforming technological barriers into breakthroughs and visionary ideas into impactful solutions. By building superintelligent systems for life and materials sciences, we seek to reshape the future of human civilization through a pioneering new research paradigm.

Management Discussion and Analysis

REVENUE

We generate revenue from (i) drug discovery solutions and (ii) intelligent robotics solutions. We provide either standalone solutions or services or a combination of our solutions or services, depending on our customers' needs.

The table below sets forth a breakdown of our revenue by business line:

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Drug discovery solutions	435,212	60,850
Intelligent robotics solutions	81,864	41,780
Total	517,076	102,630

Our revenue increased by 403.8% from RMB102.6 million for the six months ended 30 June 2024 to RMB517.1 million for the six months ended 30 June 2025.

Drug discovery solutions. Our revenue generated from our provision of drug discovery solutions increased largely by 615.2% from RMB60.9 million for the six months ended 30 June 2024 to RMB435.2 million for the six months ended 30 June 2025, primarily due to the achievement of the first-phase milestone of our major collaboration with DoveTree and a significant increase in the revenue from our antibody business.

Intelligent robotics solutions. Our revenue generated from intelligent robotics solutions increased by 95.9% from RMB41.8 million for the six months ended 30 June 2024 to RMB81.9 million for the six months ended 30 June 2025, primarily attributable to the significant growth from our automated chemical synthesis services and our XtalPi R&D solutions.

Cost of Revenue

Our cost of revenue increased by 47.7% from RMB55.5 million for the six months ended 30 June 2024 to RMB82.0 million for the six months ended 30 June 2025, primarily attributable to the increase of services we delivered.

General and Administrative Expenses

Our general and administrative expenses decreased by 14.5% from RMB234.3 million for the six months ended 30 June 2024 to RMB200.3 million for the six months ended 30 June 2025, primarily due to the absence of listing expenses during the Reporting Period and reduction in share-based compensation expenses.

Research and Development Expenses

Our R&D expenses increased by 5.3% from RMB210.4 million for the six months ended 30 June 2024 to RMB221.5 million for the six months ended 30 June 2025. The increase in our R&D spending is mainly due to increase in the number of R&D scientists employed by the Group.

Selling and Marketing Expenses

Our selling and marketing expenses increased by 16.5% from RMB34.6 million for the six months ended 30 June 2024 to RMB40.4 million for the six months ended 30 June 2025, primarily due to the increased human resources investment to enhance market penetration of our core business lines and to expand into new business areas.

Management Discussion and Analysis

Other Income

Our other income decreased by 27.7% from RMB42.4 million for the six months ended 30 June 2024 to RMB30.6 million for the six months ended 30 June 2025, primarily due to a decrease in the government grants recognised as the corresponding recognition conditions were fulfilled.

Other Gains/(Losses), Net

Our other gains/(losses), net turned from a loss of RMB2.8 million for the six months ended 30 June 2024 to a gain of RMB37.7 million for the six months ended 30 June 2025, primarily attributable to the increase in the gain on fair value of financial assets at FVTPL.

Operating Profit/(Loss)

Operating profit/(loss) turned from a loss of RMB392.9 million for the six months ended 30 June 2024 to a profit of RMB32.7 million for the six months ended 30 June 2025, primarily attributable to the abovementioned factors.

Finance Income, Net

Our finance income, net increased by 47.5% from RMB32.7 million for the six months ended 30 June 2024 to RMB48.2 million for the six months ended 30 June 2025, primarily due to the increase in interest income from our term deposits, contributed by the increase in average balance of our term deposits in total for the six months ended 30 June 2025.

Change in Fair Value of CRPS

We recognised fair value loss of CRPS of RMB875.4 million for the six months ended 30 June 2024, and we did not record any further changes in fair value of CRPS for the six months ended 30 June 2025 as such CRPS were re-designated from liabilities to equity as a result of the automatic conversion into ordinary shares upon our Listing.

Profit/(loss) for the Period

As a result of the continued expansion of our business scale and substantial revenue growth, we recorded a turnaround to profitability, from a net loss of RMB1,237.6 million for the six months ended 30 June 2024 to a net profit of RMB75.6 million for the six months ended 30 June 2025.

Non-IFRS Measure

In evaluating our business, we consider and use adjusted net profit/(loss), a non-IFRS financial measure, to supplement the review and assessment of our operating performance. We believe such non-IFRS measure facilitates comparisons of our operating performance from period to period by eliminating the potential impact of certain items. We believe that the measure provides useful information to investors in understanding and evaluating our consolidated results of operations in the same manner as they help our management. The use of the non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, as a substitute for analysis of, or superior to, our results of operations or financial conditions as reported under IFRS. In addition, the non-IFRS financial measure may be defined differently from similar terms used by other companies, and may not be comparable to other similarly titled measures used by other companies.

We define adjusted net profit/(loss) (non-IFRS measure) as net profit/(loss) adjusted by adding back (i) changes in fair value of CRPS, (ii) share-based compensation expenses, and (iii) listing expenses. Share-based compensation expenses mainly represent expenses incurred in connection with our employee stock ownership plan, reflecting equity awards granted to employees. All of our CRPS were automatically converted into ordinary shares upon the Listing and no further gains or losses related to valuation changes in these instruments will be recorded after the conversion. These two reconciling items are non-cash items. Listing expenses are expenses related to the Global Offering (as defined in the prospectus of the Company dated 4 June 2024).

Management Discussion and Analysis

The following table sets forth our adjusted net profit/(loss) (non-IFRS measure) for the periods indicated:

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Profit/(loss) for the period	75,609	(1,237,550)
Add:		
Changes in fair value of CRPS	—	875,356
Share-based compensation expenses	66,019	78,922
Listing expenses	—	31,876
Adjusted net profit/(loss) (non-IFRS measure)	141,628	(251,396)

Trade and Note Receivables

Our trade and note receivables, net of credit loss allowance, increased by 403.3% from RMB98.7 million as of 31 December 2024 to RMB497.0 million as of 30 June 2025, primarily contributed by our growth in revenue, including the trade receivable amounted to US\$51.0 million (approximately RMB365.1 million) in relation to the DoveTree collaboration, and such amount has been fully received as at the date of this report.

Intangible Assets

Intangible assets increased from RMB7.7 million as of 31 December 2024 to RMB230.9 million as of 30 June 2025, primarily due to the recognition of goodwill and intangible assets arising from the acquisition of Shanghai Siwei Medical Technology Co., Ltd. (上海四維醫學科技有限公司) (“Shanghai Siwei”) in the six months ended 30 June 2025. Further details of the acquisition are set out in the section headed “SIGNIFICANT INVESTMENTS HELD AND MATERIAL ACQUISITIONS AND DISPOSALS” below.

Other Payables and Accruals

Other payables and accruals increased by 52.4% from RMB157.1 million as of 31 December 2024 to RMB239.4 million as of 30 June 2025, primarily due to payables of RMB125.0 million arising from the acquisition of Shanghai Siwei in the six months ended 30 June 2025. As of the date of this report, such payables had been fully settled.

Bank Borrowings

Our bank borrowings increased by 441.3% from RMB51.9 million as of 31 December 2024 to RMB280.9 million as of 30 June 2025, reflecting the net increased balance of our bank borrowings. Our bank borrowings as of 30 June 2025 were denominated in Renminbi, repayable within one and a half year, and guaranteed by our subsidiaries and one patent held by one of our subsidiaries, all of which carried fixed interest rate, not more than 3.2% per annum.

Net Current Assets

We had net current assets of RMB3,035.5 million as of 31 December 2024 and RMB5,352.8 million as of 30 June 2025. The 76.3% increase in our net current assets was primarily attributable to the net proceeds from two placings of new Shares in January and February 2025, respectively.

Gearing Ratio

As at 30 June 2025, the gearing ratio (net debt (bank borrowings less Cash Balance) divided by total equity) of the Group had a net cash position (31 December 2024: net cash position). And the Cash Balance exceeded the bank borrowings by RMB5,026.8 million (31 December 2024: RMB3,071.5 million).

Management Discussion and Analysis

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended 30 June 2025, we financed our capital expenditure and working capital requirements primarily through capital contributions from our shareholders and cash inflows from our business operations. We intend to continue relying on cash flows from operations and those from financing activities including net proceeds from the Global Offering and proceeds from the placing of new shares. As of 30 June 2025, the sum of our cash and cash equivalents, term deposits, current portion of financial assets at FVTPL and restricted cash was RMB5,307.7 million, as compared with RMB3,123.4 million as of 31 December 2024.

With respect to cash management, we have established treasury and investment policies, such as our treasury management policy (資金管理制度), to monitor and manage our settlement activities and financing activities (including broadening and diversification of fundraising channels and cash management tools), and to control the risks relating to bank deposits and/or the purchase of financial instruments. We place term deposits and/or purchase financial instruments only when we have spare cash in addition to sufficient cash for our operations and in the best interest of our Company.

Cash Burn Rate and Working Capital Sufficiency

Our cash burn rate refers to the average monthly aggregate amount of (i) net cash used in operating activities, (ii) capital expenditures, and (iii) lease payment. Due to our strong revenue growth, our monthly average cash burn rate decreased by 20.0% from RMB62.1 million for the six months ended 30 June 2024 to RMB49.7 million for the six months ended 30 June 2025. Assuming our average cash burn rate going forward will be similar to the cash burn rate level in the first half of 2025, we estimate that our cash and cash equivalents, term deposits, current portion of financial assets at FVTPL and restricted cash as of 30 June 2025, being RMB5,307.7 million, will be able to maintain our financial viability for approximately 107 months. We have sufficient working capital to support our operations for approximately 8.9 years.

CONTINGENT LIABILITIES

As of 30 June 2024 and 2025, we did not have material contingent liabilities that were expected to materially and adversely affect our financial condition or results of operations.

CAPITAL EXPENDITURES

Our capital expenditures are used to expand our operations and upgrade our facilities. For the six months ended 30 June 2024 and 2025, we incurred capital expenditures of RMB34.2 million and RMB45.2 million, respectively, primarily consisting of expenditures on property, plant and equipment, and intangible assets.

FOREIGN EXCHANGE

Foreign exchange risk arises when future commercial transactions or recognised assets and liabilities are denominated in a currency that is not our entities' functional currency. We closely monitor our foreign exchange exposures and will take actions as necessary to mitigate the impact of exchange rate fluctuations.

PLEDGE OF ASSETS

As of 30 June 2025, one patent held by one of our subsidiaries was pledged by our Group (As of 31 December 2024: one patent held by one of our subsidiaries was pledged by our Group).

Management Discussion and Analysis

SIGNIFICANT INVESTMENTS HELD AND MATERIAL ACQUISITIONS AND DISPOSALS

Material acquisitions

On 10 May 2025, Shenzhen XtalPi Technology Co., Ltd. (深圳晶泰科技有限公司) (the “**Purchaser**”), a wholly-owned subsidiary of the Company, entered into the equity purchase agreement (the “**Agreement**”) with Ningbo Meishan Free Trade Port Hongmuwei Investment Management Partnership (Limited Partnership)* (寧波梅山保稅港區弘睦維投資管理合夥企業(有限合夥)) (“**Vendor 1**”), Ningbo Meishan Free Trade Port Hongmuhe Investment Management Partnership (Limited Partnership)* (寧波梅山保稅港區弘睦和投資管理合夥企業(有限合夥)) (“**Vendor 2**”), Shanghai Honghewei Medical Technology Partnership (Limited Partnership)* (上海弘和維醫學科技合夥企業 (有限合夥)) (“**Vendor 3**”, together with Vendor 1 and Vendor 2, the “**Vendors**”), Mr. Cai Zhongxi, Mr. Sheng Haifeng, Mr. Huang Yaojie, Mr. Wei Hongmin (collectively, the “**Guarantors**”), and Shanghai Siwei, pursuant to which, the Purchaser conditionally agreed to purchase, and the Vendors conditionally agreed to sell the 90% equity interest in Shanghai Siwei at an aggregate consideration of RMB250.0 million. Completion of the acquisition took place on 16 May 2025.

Pursuant to the Agreement, the Vendors and the Guarantors undertook to the Purchaser that Shanghai Siwei’s revenue from its principal business generated from projects in Shanghai region for the financial year ending 31 December 2025 (the “**Performance Guarantee Year**”) shall not be less than RMB27.0 million (the “**Guaranteed Revenue**”). Within 90 business days after the end of the Performance Guaranteed Year, the Purchaser and the Vendors shall jointly engage a third party qualified accounting firm to conduct an independent audit of Shanghai Siwei with respect to the actual realised revenue for the Performance Guarantee Year (the “**Actual Realised Revenue**”). In the event that the Actual Realised Revenue is lower than the Guaranteed Revenue, the Purchaser shall have the right to request the Vendors and the Guarantors to compensate the Purchaser the shortfall between the Guaranteed Revenue and the Actual Realised Revenue by cash.

For further details, please refer to the announcement of the Company dated 11 May 2025.

Significant investments

The following table summarises the information regarding the Group’s investments classified as financial assets at FVTPL with a carrying amount that accounted for 5% or more of the Group’s total assets as of 30 June 2025:

Product invested	Description of the underlying investments	Principal	Cost of investment	Fair value as of 30 June 2025	Percentage of fair value relative to total assets	Fair value gain	Realised gain
		amount held as of 30 June 2025				during the six months ended 30 June 2025 (unrealised)	
		RMB (million)	RMB (million)	RMB (million)		RMB (million)	RMB (million)
Notes issued by Fosun Hani Global Limited	The product primarily invests in US Dollar time deposits, US treasury bills, US treasury notes and US treasury bonds, fixed rate notes and private equity assets.	575.2	575.2	595.9	7.7%	15.5	12.6

The investments in wealth management products under financial assets at FVTPL were made for treasury management purposes to maximise return on available funds held by the Group.

Save as disclosed above, there were no other significant investments held as at 30 June 2025, and no material acquisitions or disposals of subsidiaries, associates or joint ventures for the six months ended 30 June 2025.

Management Discussion and Analysis

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

We did not have any concrete plan for material investments or acquisition of capital assets other than those mentioned in this report, the prospectus of the Company dated 4 June 2024 or in our previous announcements during the six months ended 30 June 2025, including the announcements on the two placings of new Shares in January and February 2025, respectively.

EMPLOYEES AND REMUNERATION POLICY

As of 30 June 2025, we had a total of 1,054 employees. For the six months ended 30 June 2025, the total remuneration cost incurred by the Group was RMB316.8 million (six months ended 30 June 2024: RMB315.5 million).

The remuneration of our Group's employees comprises salaries, bonuses, employees' provident fund, share-based payment, and social security contributions and other welfare payments, which are determined by their responsibilities, qualifications, positions and seniority. In accordance with applicable laws and regulations, we make contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group's employees.

We provide formal and comprehensive company-level and department-level training to our new employees, followed by on-the-job training. We also provide training and development programs to our employees from time-to-time to ensure their awareness and compliance with our various policies and procedures. Some of the training is conducted jointly by departments serving different functions but working with or supporting each other in our day-to-day operations.

USE OF PROCEEDS FROM LISTING

The net proceeds raised from the Global Offering (including net proceeds raised from the shares issued as a result of the partial exercise of the over-allotment option) (the "IPO Proceeds") were approximately HK\$915.18 million. As of 30 June 2025, details of the utilisation of such net proceeds are as follows:

Use of proceeds from Global Offering	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceeds	Utilised net proceeds as of 30 June 2025 (HK\$ million)	Unutilised net proceeds as of 30 June 2025 (HK\$ million)	Expected timeline for utilising the remaining balance of net proceeds
Enhancing R&D capabilities and solutions provision	686.39	75%	150.49	535.90	By 2029
(i) upgrading and optimising the quantum physics-based closed-loop integrated technology platform:					
– recruit automation-related talents and compound talents	91.52	10%	7.02	84.50	
– build automated workstations, centrifuges and other ancillary equipment	91.52	10%	4.76	86.76	
– build an intelligent computing center and further upgrade and improve the intelligent computing resource allocation system	183.04	20%	31.81	151.23	
(ii) enhancing the ability to develop solutions in the biotechnology, pharmaceutical, materials science (including agritech, energy and new chemicals, and cosmetics):					
– recruit five professionals in the biotechnology and pharmaceutical sectors and build a team that can fully operate and support the R&D and delivery of materials	137.28	15%	18.51	118.77	
– purchase protein chromatography purifiers, cryo-EM accessories, flow cytometers, mass spectrometers, microplate readers and other instruments	109.82	12%	15.18	94.64	

Management Discussion and Analysis

Use of proceeds from Global Offering	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceeds	Utilised net proceeds as of 30 June 2025 (HK\$ million)	Unutilised net proceeds as of 30 June 2025 (HK\$ million)	Expected timeline for utilising the remaining balance of net proceeds
(iii) lease of properties for and improvements of the R&D centers in Shanghai and Shenzhen	73.21	8%	73.21	—	
Improving commercialisation capability in and beyond China	137.28	15%	40.63	96.64	By 2029
(i) expanding business development and marketing team with a focus on development of relationship with potential customers that are famous pharmaceutical/contract research organisation/contract development and manufacturing organisation companies in China and overseas countries or regions, especially in the United States	73.21	8%	9.22	63.99	
(ii) business development activities overseas in addition to the recruitment of business development and marketing staff as mentioned above	64.06	7%	31.41	32.65	
For working capital and general corporate purposes	91.52	10%	91.52	—	
Total	915.18	100%	282.64	632.54	

Notes:

- (1) The sum of the data may not add up to the total due to rounding.
- (2) The above expected time frame of unutilised amount is based on the Directors' best estimation barring unforeseen circumstances, and would be subject to change based on the future development of the Group and the market conditions.

As of 30 June 2025, the Directors were not aware of any material change in the planned use of the net proceeds. All the unused net proceeds have been deposited in short-term interest-bearing accounts at licensed commercial banks and/or other authorised financial institutions maintained by the Group.

USE OF PROCEEDS FROM PLACINGS

January Placing

On 19 January 2025, the Company announced the placing of 264,000,000 new Shares to not less than six placees at the placing price of HK\$4.28 per Share (the "January Placing"), which was completed on 24 January 2025. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the placees were professional, institutional, or other investors that are, together with their respective ultimate beneficial owners, third parties independent of the Company and its connected persons.

The aggregate nominal value of the Shares under the January Placing is US\$2,640. The market price of the Shares as quoted on the Stock Exchange on 17 January 2025, being the last trading date immediately prior to the date on which the terms of the January Placing were fixed, was HK\$4.65 per Share.

The gross proceeds from the January Placing amounted to approximately HK\$1,130.00 million, and the net proceeds (after deducting all applicable costs and expenses, including commission and levies) arising from the January Placing amounted to approximately HK\$1,125.00 million. On this basis, the net price per Share under the January Placing was approximately HK\$4.26.

Management Discussion and Analysis

The Company intends to use the net proceeds from the January Placing primarily for (i) continuous product iterations and upgrades to enhance its research and development technological capabilities and solution capabilities, (ii) facilitating the commercialization of the Company, strengthening external collaborations, and expanding the scale and market share of the Company, (iii) investing in potential opportunities, talent attraction and introduction, working capital replenishment and general corporate purposes.

To the extent that the net proceeds from the January Placing are not immediately used for the purposes described above, the Company may hold such proceeds in short-term deposits or purchase short-term wealth management products so long as it is deemed to be in the best interests of the Company.

As of 30 June 2025, approximately HK\$643.57 million of the proceeds from the January Placing have been utilised, details of which are set out below:

Use of proceeds from the January Placing	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceeds	Utilised net proceeds as of 30 June 2025 (HK\$ million)	Unutilised net proceeds as of 30 June 2025 (HK\$ million)	Expected timeline for utilising the remaining balance of net proceeds
(i) continuous product iterations and upgrades to enhance its research and development technological capabilities and solution capabilities	247.50	22%	240.73	6.77	By 2027
(ii) facilitating the commercialisation of the Company, strengthening external collaborations, and expanding the scale and market share of the Company	506.25	45%	31.59	474.66	By 2027
(iii) investing in potential opportunities, talent attraction and introduction, working capital replenishment and general corporate purposes	371.25	33%	371.25	—	
Total	1,125.00	100%	643.57	481.43	

Notes:

- (1) The sum of the data may not add up to the total due to rounding.
- (2) The above expected time frame of unutilised amount is based on the Directors' best estimation barring unforeseen circumstances, and would be subject to change based on the future development of the Group and the market conditions.

February Placing

On 19 February 2025, the Company announced the placing of 342,288,000 new Shares to not less than six placees at the placing price of HK\$6.10 per Share (the "**February Placing**"), which was completed on 25 February 2025. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the placees were professional, institutional, or other investors that are, together with their respective ultimate beneficial owners, third parties independent of the Company and its connected persons.

The aggregate nominal value of the Shares under the February Placing is US\$3,422.88. The market price of the Shares as quoted on the Stock Exchange on 18 February 2025, being the date on which the terms of the February Placing were fixed, was HK\$6.48 per Share.

Management Discussion and Analysis

The gross proceeds from the February Placing amounted to approximately HK\$2,088.00 million, and the net proceeds (after deducting all applicable costs and expenses, including commission and levies) arising from the February Placing amounted to approximately HK\$2,080.00 million. On this basis, the net price per Share under the February Placing was approximately HK\$6.08.

The Company intends to use the net proceeds from the February Placing primarily for (i) continuous product iterations and upgrades to enhance its research and development technological capabilities and solution capabilities, and data generation and model building; (ii) product commercialisation and business development, strengthening business collaborations with external parties and partners which are engaged in similar and mutually beneficial industries as the Group, and expanding the scale and market share of the Company; and (iii) acquisitions and investing in potential opportunities, talent attraction and introduction, working capital replenishment and general corporate purposes.

To the extent that the net proceeds from the February Placing are not immediately used for the purposes described above, the Company may hold such proceeds in short-term deposits or purchase short-term wealth management products so long as it is deemed to be in the best interests of the Company and its shareholders.

As of 30 June 2025, approximately HK\$507.66 million of the proceeds from the February Placing have been utilised, details of which are set out below:

Use of proceeds from the February Placing	Amount of net proceeds for planned applications (HK\$ million)	Percentage of total net proceeds	Utilised net proceeds as of 30 June 2025 (HK\$ million)	Unutilised net proceeds as of 30 June 2025 (HK\$ million)	Expected timeline for utilising the remaining balance of net proceeds
(i) continuous product iterations and upgrades to enhance its research and development technological capabilities and solution capabilities, and data generation and model building	832.00	40%	—	832.00	By 2034
(ii) product commercialisation and business development, strengthening business collaborations with external parties and partners which are engaged in similar and mutually beneficial industries as the Group, and expanding the scale and market share of the Company	416.00	20%	—	416.00	By 2034
(iii) acquisitions and investing in potential opportunities, talent attraction and introduction, working capital replenishment and general corporate purposes	832.00	40%	507.66	324.34	By 2034
Total	2,080.00	100%	507.66	1,572.34	

Notes:

- (1) The sum of the data may not add up to the total due to rounding.
- (2) The above expected time frame of unutilised amount is based on the Directors' best estimation barring unforeseen circumstances, and would be subject to change based on the future development of the Group and the market conditions.

As of 30 June 2025, the Directors were not aware of any material change in the planned use of the net proceeds. To the extent that the net proceeds from the Placings are not immediately used for the purposes described above, the Company may hold such proceeds in short-term deposits or purchase short-term wealth management products so long as it is deemed to be in the best interests of the Company.

Corporate Governance and Other Information

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS AND CHIEF EXECUTIVE OF THE COMPANY IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As of 30 June 2025, the interests and short positions of the Directors and chief executive of the Company in any of the Shares, underlying Shares or debentures of the Company or any of its associated corporation (within the meaning of Part XV of the SFO) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Interests in Shares and underlying Shares

Name of Director	Capacity/nature of interest	Number of Shares/ underlying Shares ⁽¹⁾	Percentage of shareholding in the Company ⁽²⁾
Dr. Wen Shuhao	Beneficial owner ⁽³⁾	81,093,362 (L)	2.02%
	Founder of trust ⁽⁴⁾	222,126,400 (L)	5.53%
	Interest in controlled corporation ⁽⁵⁾⁽⁶⁾	447,615,658 (L)	11.14%
Dr. Ma Jian	Beneficial owner ⁽⁷⁾	45,230,342 (L)	1.13%
	Founder of trust ⁽⁸⁾	122,908,500 (L)	3.06%
	Interest in controlled corporation ⁽⁹⁾	59,103,125 (L)	1.47%
Dr. Lai Lipeng	Beneficial owner ⁽¹⁰⁾	32,315,661 (L)	0.80%
	Founder of trust ⁽¹¹⁾	87,814,140 (L)	2.18%
Dr. Jiang Yide Alan	Founder of trust ⁽¹²⁾	3,800,000 (L)	0.09%
	Beneficiary of trust ⁽¹³⁾	3,800,000 (L)	0.09%
	Interest in controlled corporation ⁽¹⁴⁾	2,400,000 (L)	0.06%
Mr. Law Cheuk Kin Stephen	Beneficiary of trust ⁽¹⁵⁾	900,000 (L)	0.02%
Ms. Chan Wing Ki	Beneficiary of trust ⁽¹⁶⁾	450,000 (L)	0.01%
Mr. Chow Ming Sang	Beneficiary of trust ⁽¹⁷⁾	450,000 (L)	0.01%

Notes:

(1) The letter "L" denotes long positions.

(2) Calculated based on 4,019,811,761 Shares in issue as of 30 June 2025.

(3) Representing 81,093,362 Shares underlying the options granted to Dr. Wen Shuhao under the Pre-IPO ESOP.

(4) QuantumPharm Holdings is held as to 99% by WSH Family Holdings, which is the holding vehicle of TMF (Cayman) Ltd. TMF (Cayman) Ltd. is the trustee of the WSH Family Trust, a discretionary trust established by Dr. Wen Shuhao as settlor. Under the SFO, Dr. Wen Shuhao is deemed to have a long position in 222,126,400 Shares.

(5) QuantumPharm Roc, the shareholding platform for the Pre-IPO ESOP which holds the Shares underlying the options granted thereunder for the benefit of the grantees, is wholly owned by QuantumPharm Holdings. Under the SFO, Dr. Wen Shuhao is deemed to be interested in the 236,893,018 Shares in which QuantumPharm Roc is interested.

Corporate Governance and Other Information

- (6) Pursuant to the powers of attorney executed by (i) Dr. Ma Jian and Crete Helix; and (ii) Dr. Lai Lipeng and SevensingBAlpha in favor of Dr. Wen Shuhao and QuantumPharm Holdings, QuantumPharm Holdings is authorized to exercise all the voting rights attached to the Shares held by Crete Helix and SevensingBAlpha. Under the SFO, Dr. Wen Shuhao is deemed to be interested in the 122,908,500 Shares in which Crete Helix is interested and the 87,814,140 Shares in which SevensingBAlpha is interested.
- (7) Representing 45,230,342 Shares underlying the options granted to Dr. Ma Jian under the Pre-IPO ESOP.
- (8) Crete Helix is held as to 99% by MH International Holdings, which is the holding vehicle of TMF (Cayman) Ltd. TMF (Cayman) Ltd. is the trustee of the MH Fund Trust, a discretionary trust established by Dr. Ma Jian as settlor. Under the SFO, Dr. Ma Jian is deemed to be interested in the 122,908,500 Shares in which Crete Helix is interested.
- (9) Representing 59,103,125 Shares underlying the options granted under the Pre-IPO ESOP held by QuantumPharm Employee Holdings, a holding vehicle wholly owned by the trustee of the QuantumPharm Employee Benefit Trust for the benefit of 13 employees and ex-employees of the Group. In accordance with the terms of the trust deed of the QuantumPharm Employee Benefit Trust dated 28 June 2021, Dr. Ma Jian, being the sole member of the advisory committee established by the Company, has the sole power to make all decisions relating to the exercise of any voting and other rights of the properties held under the trust and to give instructions and directions to the trustee for the execution of such decisions.
- (10) Representing 32,315,661 Shares underlying the options granted to Dr. Lai Lipeng under the Pre-IPO ESOP.
- (11) SevensingBAlpha is held as to 99% by LPHappy Holding, which is the holding vehicle of TMF (Cayman) Ltd. TMF (Cayman) Ltd. is the trustee of the LPHappy Family Trust, a discretionary trust established by Dr. Lai Lipeng as settlor. Under the SFO, Dr. Lai Lipeng is deemed to be interested in the 87,814,140 Shares in which SevensingBAlpha is interested.
- (12) Representing 3,800,000 Shares underlying the options granted under the Pre-IPO ESOP which are held by a spousal lifetime access trust established by Dr. Jiang Yide Alan for the benefit of his spouse. Under the SFO, Dr. Jiang Yide Alan is deemed to be interested in the Shares in which the aforesaid trust is interested.
- (13) Representing 3,800,000 Shares underlying the options granted under the Pre-IPO ESOP which are held by a spousal lifetime access trust established by the spouse of Dr. Jiang Yide Alan for the benefit of Dr. Jiang Yide Alan. Under the SFO, Dr. Jiang Yide Alan is deemed to be interested in the Shares in which the aforesaid trust is interested.
- (14) Representing 2,400,000 Shares underlying the options granted under the Pre-IPO ESOP which are held by ASJX Envision LLC. ASJX Envision LLC is held as to 40% by a revocable trust established by Dr. Jiang Yide Alan, 40% by a revocable trust established by the spouse of Dr. Jiang Yide Alan and 20% by a family trust established by them. Under the SFO, Dr. Jiang Yide Alan is deemed to be interested in the Shares in which ASJX Envision LLC is interested.
- (15) Representing 900,000 Shares underlying the RSUs granted to Mr. Law Cheuk Kin Stephen under the Post-IPO RSU Scheme.
- (16) Representing 450,000 Shares underlying the RSUs granted to Ms. Chan Wing Ki under the Post-IPO RSU Scheme.
- (17) Representing 450,000 Shares underlying the RSUs granted to Mr. Chow Ming Sang under the Post-IPO RSU Scheme.

Save as disclosed above, as of 30 June 2025, to the best knowledge of the Directors and chief executive of the Company, none of the Directors and chief executive of the Company had any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporation (within the meaning of Part XV of the SFO) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

Corporate Governance and Other Information

INTERESTS OF THE SUBSTANTIAL SHAREHOLDERS IN THE SHARES AND UNDERLYING SHARES

As of 30 June 2025, so far as the Directors were aware, the following persons (not being a Director or chief executive of the Company) had or were deemed or taken to have interests or short positions in the Shares or the underlying Shares which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were required, pursuant to section 362 of the SFO, to be entered in the register referred to therein:

Interests in the Shares

Name of Shareholder	Nature of interest	Number of Shares ⁽¹⁾	Percentage of shareholding in the Company ⁽²⁾
WSH Family Holdings Limited	Interest in controlled corporation ⁽³⁾	669,742,058 (L)	16.66%
TMF (Cayman) Ltd.	Trustee of trusts ⁽³⁾	669,742,058 (L)	16.66%
QuantumPharm Holdings Limited	Beneficial owner	222,126,400 (L)	5.53%
	Interest in controlled corporation ⁽⁴⁾⁽⁵⁾	447,615,658 (L)	11.14%
QuantumPharm Roc Holdings Limited	Beneficial owner	236,893,018 (L)	5.89%
5Y Capital GP Limited	Interest in controlled corporation ⁽⁶⁾	229,291,801 (L)	5.70%
Liu Qin	Interest in controlled corporation ⁽⁶⁾	229,291,801 (L)	5.70%
Ni Yuanyuan	Interest of spouse ⁽⁷⁾	229,291,801 (L)	5.70%

Notes:

- (1) The letter "L" denotes long positions.
- (2) Calculated based on 4,019,811,761 Shares in issue as of 30 June 2025.
- (3) QuantumPharm Holdings is held as to 99% by WSH Family Holdings, which is the holding vehicle of TMF (Cayman) Ltd. TMF (Cayman) Ltd., being the trustee of the WSH Family Trust, a discretionary trust established by Dr. Wen Shuhao as settlor. Under the SFO, each of WSH Family Holdings and TMF (Cayman) Ltd. is deemed to be interested in the Shares in which QuantumPharm Holdings is interested.
- (4) QuantumPharm Roc, being the shareholding platform for the Pre-IPO ESOP which holds the Shares underlying the options granted thereunder for the benefit of the grantees, is wholly owned by QuantumPharm Holdings. Under the SFO, QuantumPharm Holdings is deemed to be interested in the 236,893,018 Shares in which QuantumPharm Roc is interested.
- (5) Pursuant to the powers of attorney executed by (i) Dr. Ma Jian and Crete Helix; and (ii) Dr. Lai Lipeng and SevensingBAlpha in favor of Dr. Wen Shuhao and QuantumPharm Holdings, QuantumPharm Holdings is authorized to exercise all the voting rights attached to the Shares held by Crete Helix and SevensingBAlpha. Under the SFO, QuantumPharm Holdings is deemed to be interested in the 122,908,500 Shares in which Crete Helix is interested and the 87,814,140 Shares in which SevensingBAlpha is interested.
- (6) Evolution Fund I, L.P., Evolution Special Opportunity Fund I, L.P. and Evolution Fund I Co-investment, L.P., are exempted limited partnerships established under the laws of the Cayman Islands and are controlled by 5Y Capital GP Limited, as their general partner. Liu Qin is entitled to exercise or control the exercise of one-half of the voting power of all issued shares in 5Y Capital GP Limited at its general meeting. Under the SFO, each of 5Y Capital GP Limited and Liu Qin is deemed to be interested in the Shares in which Evolution Fund I, L.P., Evolution Special Opportunity Fund I, L.P. and Evolution Fund I Co-investment, L.P. are interested.
- (7) Ni Yuanyuan is the spouse of Liu Qin. Under the SFO, Ni Yuanyuan is deemed to be interested in the Shares in which Liu Qin is interested.

Save as disclosed above, as of 30 June 2025, the Directors were not aware of any other person (not being a Director or chief executive of the Company) who had an interest or short position in the Shares or the underlying Shares which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were required, pursuant to section 362 of the SFO, to be entered in the register referred to therein.

Corporate Governance and Other Information

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2025, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares). As of 30 June 2025, the Company did not hold any treasury shares.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct for dealings in the securities of the Company by the Directors.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the six months ended 30 June 2025.

SHARE INCENTIVE SCHEMES

During the six months ended 30 June 2025 and up to the date of this interim report, we have three share schemes in effect.

1. Pre-IPO ESOP

The Pre-IPO ESOP was adopted by the Shareholders on 14 July 2021 and amended on 5 August 2021. No further awards was or will be granted under the Pre-IPO ESOP after the Listing. The terms of the Pre-IPO ESOP are not subject to the provisions of Chapter 17 of the Listing Rules.

Details of the outstanding options granted under the Pre-IPO ESOP as of 30 June 2025 are set out below:

Name of grantee	Date of grant	Exercise price (US\$ per share)	Vesting status	Exercise period	Number of Shares underlying options as of 1 January 2025	Number of options exercised during the six months ended 30 June 2025	Number of options cancelled/ forfeited during the six months ended 30 June 2025	Number of Shares underlying the outstanding options as of 30 June 2025
Directors								
Dr. Wen Shuhao	15 April 2021	0.18792135	Fully vested	15 April 2021–14 April 2031	38,183,588	–	–	38,183,588
	24 November 2023	0.2467842	50% will be vested after 24 months commencing from the Listing Date, 25% will be vested after 36 months commencing from the Listing Date and 25% will be vested after 48 months commencing from the Listing Date	24 November 2023–23 November 2033	42,909,774	–	–	42,909,774
Dr. Ma Jian	15 April 2021	0.18792135	Fully vested	15 April 2021–14 April 2031	21,436,379	–	–	21,436,379
	24 November 2023	0.2467842	50% will be vested after 24 months commencing from the Listing Date, 25% will be vested after 36 months commencing from the Listing Date and 25% will be vested after 48 months commencing from the Listing Date	24 November 2023–23 November 2033	23,793,963	–	–	23,793,963

Corporate Governance and Other Information

Name of grantee	Date of grant	Exercise price (US\$ per share)	Vesting status	Exercise period	Number of Shares underlying outstanding options as of 1 January 2025	Number of options exercised during the six months ended 30 June 2025	Number of options cancelled/ forfeited during the six months ended 30 June 2025	Number of Shares underlying the outstanding options as of 30 June 2025
Dr. Lai Lipeng	15 April 2021	0.18792135	Fully vested	15 April 2021–14 April 2031	15,315,639	–	–	15,315,639
	24 November 2023	0.2467842	50% will be vested after 24 months commencing from the Listing Date, 25% will be vested after 36 months commencing from the Listing Date and 25% will be vested after 48 months commencing from the Listing Date	24 November 2023–23 November 2033	17,000,022	–	–	17,000,022
Dr. Jiang Yide Alan	1 October 2015	0.0008	Fully vested	1 October 2015–14 July 2031	10,000,000 ⁽¹⁾	–	–	10,000,000
Consultants								
2 grantees ⁽²⁾	3 September 2019	0.26309	Fully vested	3 September 2019–2 September 2029	53,215	–	–	53,215
	3 September 2019	0.26309	Fully vested	3 September 2019–2 September 2029	478,934	–	–	478,934
Ex-employees and other employees (who are not Directors or consultants)								
167 grantees (range of 1 to 499,999 Shares underlying the options granted)	26 November 2015 to 1 March 2024	0.00032458 to 0.527	A, B, C, D ⁽⁴⁾	Within 10 years from the date of grant	17,943,004	2,730,500	322,500	14,890,004
19 grantees (range of 500,000 to 999,999 Shares underlying the options granted)	1 February 2017 to 1 March 2024	0.00283995 to 0.462	A, B, C ⁽⁴⁾	Within 10 years from the date of grant	6,382,000	1,756,000	470,000	4,156,000
11 grantees (range of 1,000,000 to 4,999,999 Shares underlying the options granted)	26 November 2015 to 1 March 2024	0.00032458 to 0.527	A, B, C ⁽⁴⁾	Within 10 years from the date of grant	39,682,925	7,664,000	1,895,000	30,123,925
3 grantees (range of 5,000,000 Shares underlying the options granted)	1 March 2016	0.00150	Fully vested	1 March 2016–28 February 2026	8,000,000 ⁽²⁾	–	–	8,000,000
	1 February 2017	0.00150	Fully vested	1 February 2017–31 January 2027	7,000,000 ⁽²⁾	–	–	7,000,000
	1 March 2017	0.00150	Fully vested	1 March 2017–28 February 2027	5,000,000 ⁽²⁾	2,000,000	–	3,000,000

Corporate Governance and Other Information

Name of grantee	Date of grant	Exercise price (US\$ per share)	Vesting status	Exercise period	Number of Shares underlying outstanding options as of 1 January 2025	Number of options exercised during the six months ended 30 June 2025	Number of options cancelled/ forfeited during the six months ended 30 June 2025	Number of Shares underlying the outstanding options as of 30 June 2025
2 grantees (senior management)	1 October 2015	0.00001	Fully vested	1 October 2015–30 September 2025	22,837,200 ⁽²⁾	—	—	22,837,200
	1 January 2021	0.18792135	Fully vested	1 January 2021–31 December 2030	12,000,000 ⁽¹⁾	12,000,000	—	—
Total					288,016,643	26,150,500	2,687,500	259,178,643

Notes:

- Pursuant to the powers of attorney granted by Mr. Tam Man Hong and Dr. Jiang Yide Alan in favor of Dr. Wen Shuhao on 28 May 2024, respectively, Dr. Wen Shuhao is unconditionally, indefinitely and irrevocably authorized and appointed to exercise all the voting rights attached to: (i) the Shares underlying the vested outstanding options owned by them; and (ii) the Shares transferred or issued to them upon the exercise of the vested outstanding options, except for any matter the outcome of the vote on which will disproportionately, materially and adversely affect the grantors, as compared to Dr. Wen Shuhao or any other Shareholder. The powers of attorney shall be valid from the Listing Date for an indefinite term. Accordingly, the voting rights of the Shares underlying the vested outstanding options will be entrusted to Dr. Wen Shuhao upon the Listing.
- Representing the Shares held by QuantumPharm Roc underlying options held by QuantumPharm Employee Holdings, a holding vehicle wholly owned by TMF Trust (HK) Limited as trustee of the QuantumPharm Employee Benefit Trust for the benefit of 13 employees and ex-employees of the Group. In accordance with the terms of the trust deed of the QuantumPharm Employee Benefit Trust dated 28 June 2021, Dr. Ma Jian, being the sole member of the advisory committee established by the Company, has the sole power to make all decisions relating to the exercise of any voting and other rights of the properties held under the trust and to give instructions and directions to the trustee for the execution of such decisions.
- The two consultants were one of the advisory board members of XtalPi Inc., a direct wholly-owned subsidiary of the Company. They were responsible for providing professional advice, opinion and guidance to our technology developments and applications in the pharmaceutical and materials design industry and market, making recommendations and referrals on scientific researchers and industry leaders and promoting our scientific exchanges and collaborations in pharmaceutical innovation within China and the United States.
- Please refer to the different categories of vesting schedules below:

Category Vesting schedule

- | | |
|---|--|
| A | Four equal tranches with the vesting date on the first, second, third and fourth anniversary date of the grant date. |
| B | 50% will be vested at the second anniversary of the grant date, 25% will be vested at the third anniversary of the grant date, and 25% will be vested at the fourth anniversary of the grant date. |
| C | 25% is vested immediately on the grant date, and the remaining 75% will be vested in three equal tranches with the vesting date on the first, second and third anniversary date of the grant date. |
| D | 50% is vested immediately on the grant date, and the remaining 50% will be vested in two equal tranches with vesting date on the first and second anniversary date of the grant date. |

- The weighted average closing price of the Shares immediately before the dates on which the options were exercised was HK\$5.36.

Corporate Governance and Other Information

2. Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme was adopted by the Company pursuant to the resolutions of the Shareholders passed on 28 May 2024.

As of 30 June 2025, no option had been granted or agreed to be granted under the Post-IPO Share Option Scheme.

3. Post-IPO RSU Scheme

The Post-IPO RSU Scheme was adopted by the Company pursuant to the resolutions of the Shareholders passed on 28 May 2024.

Details of the outstanding RSUs granted under the Post-IPO RSU Scheme as of 30 June 2025 are set out below:

Name of grantee	Date of grant	Purchase price (HK\$ per share)	Number of unvested RSUs as of 1 January 2025	Number of RSUs granted during the six months ended 30 June 2025	Number of RSUs vested during the six months ended 30 June 2025	Number of RSUs cancelled during the six months ended 30 June 2025	Number of RSUs lapsed during the six months ended 30 June 2025	Number of unvested RSUs as of 30 June 2025
Directors								
Mr. Law Cheuk Kin Stephen	20 December 2024 ⁽¹⁾	Nil	900,000	-	-	-	-	900,000
Ms. Chan Wing Ki	20 December 2024 ⁽¹⁾	Nil	450,000	-	-	-	-	450,000
Mr. Chow Ming Sang	20 December 2024 ⁽¹⁾	Nil	450,000	-	-	-	-	450,000
Total			1,800,000	-	-	-	-	1,800,000

Note:

- (1) Subject to the terms of the Post-IPO RSU Scheme, the vesting period of the RSUs granted is as follows: 25% of the RSUs granted shall vest on each of (i) 20 December 2025, (ii) 20 December 2026, (iii) 20 December 2027, and (iv) 20 December 2028. The vesting of the RSUs is not subject to any performance targets.

Number of Share Available for Future Grant

The number of options and awards available for grant under the Scheme Limit as of 1 January 2025 and 30 June 2025 are set out below:

	Scheme Limit⁽¹⁾	
	As of 1 January 2025	As of 30 June 2025
Number of options and awards available for grant	202,606,365	202,606,365
	underlying Shares	underlying Shares

Note:

- (1) No service provider sublimit was set under the Scheme Limit.

For the purpose of Rule 17.07(3) of the Listing Rules, as no option or award was granted under any of the share schemes of the Company during the Reporting Period, the number of Shares that may be issued in respect of options and awards granted during the Reporting Period divided by the weighted average number of Shares of the relevant class in issue (excluding any treasury shares) for the Reporting Period is therefore not applicable.

Corporate Governance and Other Information

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company aims to achieve high standards of corporate governance, which are crucial to the Company's development and safeguard the interests of the Company's shareholders. The Company has applied the principles of good corporate governance and adopted the code provisions of the Corporate Governance Code as its own code of corporate governance. The Company has complied with all applicable code provisions set out in Part 2 of the Corporate Governance Code during the six months ended 30 June 2025. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

REVIEW OF INTERIM RESULTS

The Company has established the Audit Committee with written terms of reference in compliance with the Corporate Governance Code. The Audit Committee currently consists of three independent non-executive Directors, namely, Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang. The Audit Committee is chaired by Mr. Law Cheuk Kin Stephen. The Audit Committee has reviewed the unaudited consolidated interim financial statements of the Group for the Reporting Period and discussed with the management and auditors of the Company the accounting principles and practices adopted by the Group.

The interim financial information for the Reporting Period has not been audited but has been reviewed by PricewaterhouseCoopers, the auditor of the Company, in accordance with International Standard on Review Engagement 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the International Auditing and Assurance Standards Board.

SUBSEQUENT EVENTS

Subsequent to 30 June 2025 and up to the date of this report, the Group has entered into several equity related investments with several entities and subscribed several wealth management products with total consideration of approximately RMB122.5 million and RMB316.4 million, respectively.

Save as disclosed above, no significant events occurred which have material impact on the performance of the Group subsequent to 30 June 2025 and up to the date of this report.

INTERIM DIVIDEND

The Board does not recommend the distribution of any interim dividend for the six months ended 30 June 2025 (For the six months ended 30 June 2024: nil).

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

CHANGES TO THE DIRECTORS' INFORMATION

In June 2025, Ms. Chan Wing Ki ceased to act as a member of the General Committee of The Chamber of Hong Kong Listed Companies.

With effect from 31 August 2025, Mr. Chow Ming Sang resigned as an independent non-executive director of Teamway International Group Holdings Limited, a company listed on the Stock Exchange (stock code: 1239).

Save as disclosed above, the Directors have confirmed that no information is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

FORWARD-LOOKING STATEMENTS

This interim report contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

APPRECIATION

The Board would like to express its sincere gratitude to our Shareholders, management team, employees, business partners and customers for their support and contribution to the Group.

By order of the Board

XtalPi Holdings Limited

Dr. Wen Shuhao

Chairman of the Board and Executive Director

Hong Kong, 27 August 2025

Report on Review of Interim Financial Information

To the Board of Directors of XtalPi Holdings Limited

(incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 33 to 67, which comprises the condensed consolidated balance sheet of XtalPi Holdings Limited (the “**Company**”) and its subsidiaries (together, the “**Group**”) as at 30 June 2025 and the condensed consolidated statement of profit or loss, the condensed consolidated statement of comprehensive income, the condensed consolidated statement of changes in equity and the condensed consolidated statement of cash flows for the six-month period then ended, and notes, comprising material accounting policy information and other explanatory information. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 “Interim Financial Reporting”. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, 27 August 2025

Condensed Consolidated Statement of Profit or Loss

For the six months ended 30 June

	Note	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenues	4	517,076	102,630
Cost of revenues	5	(81,959)	(55,478)
General and administrative expenses	5	(200,333)	(234,314)
Research and development expenses	5	(221,527)	(210,390)
Selling and marketing expenses	5	(40,354)	(34,638)
Impairment losses on financial assets		(8,523)	(270)
Other income	6	30,646	42,360
Other gains/(losses), net	7	37,702	(2,761)
Operating profit/(loss)		32,728	(392,861)
Finance income		51,874	36,414
Finance expenses		(3,654)	(3,733)
Finance income, net		48,220	32,681
Changes in fair value of convertible redeemable preferred shares	17	—	(875,356)
Impairment provision for investment in an associate		(2,348)	—
Share of net losses of investments accounted for using equity method		(2,991)	(2,014)
Profit/(loss) before income tax		75,609	(1,237,550)
Income tax expense	8	—	—
Profit/(loss) for the period		75,609	(1,237,550)
Profit/(loss) for the period attributable to:			
Equity holders of the Company		82,795	(1,237,016)
Non-controlling interests		(7,186)	(534)
		75,609	(1,237,550)
Earnings/(loss) per share for profit/(loss) attributable to equity holders of the Company	9		
Basic earnings/(loss) per share		2.30	(169.65)
Diluted earnings/(loss) per share		2.20	(169.65)
		RMB Cent	RMB Cent

The above consolidated statement of profit or loss should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Comprehensive Income

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Profit/(loss) for the period	75,609	(1,237,550)
Other comprehensive income		
Items that will not be reclassified to profit or loss		
— Changes in fair value of convertible redeemable preferred shares due to own credit risk	—	(19,774)
— Currency translation differences	(69,110)	(10,924)
Items that may be subsequently reclassified to profit or loss		
— Currency translation differences	26,619	(11,465)
Other comprehensive income for the period, net of tax	(42,491)	(42,163)
Total comprehensive income/(loss) for the period, net of tax	33,118	(1,279,713)
Total comprehensive income/(loss) for the period attributable to:		
Equity holders of the Company	40,455	(1,279,395)
Non-controlling interest	(7,337)	(318)
	33,118	(1,279,713)

The above condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

Condensed Consolidated Balance Sheet

		As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
	Note		
Assets			
Non-current assets			
Property, plant and equipment	11	292,558	320,397
Right-of-use assets	11	77,710	90,920
Intangible assets	11	230,862	7,743
Investments accounted for using the equity method		50,350	25,836
Financial assets at fair value through profit or loss	12	1,077,693	555,060
Deferred income tax assets		1,339	—
Prepayments	14	19,004	18,251
Term deposits		—	21,266
		1,749,516	1,039,473
Current assets			
Contract costs		32,715	25,671
Inventories		27,076	—
Trade and note receivables	13	497,007	98,746
Contract assets		3,586	3,586
Prepayments, deposits and other receivables	14	100,528	85,132
Financial assets at fair value through profit or loss	12	1,841,124	1,786,049
Restricted cash		2,565	797
Term deposits		1,152,335	149,138
Cash and cash equivalents		2,311,688	1,166,148
		5,968,624	3,315,267
Total assets		7,718,140	4,354,740
Equity			
Equity attributable to equity holders of the Company			
Share capital	18	280	237
Other reserves	19	15,483,819	12,535,678
Accumulated losses		(8,489,366)	(8,572,161)
		6,994,733	3,963,754
Non-controlling interests		33,933	28,553
Total equity		7,028,666	3,992,307

Condensed Consolidated Balance Sheet

		As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
	Note		
Liabilities			
Non-current liabilities			
Long-term bank borrowings		7,000	—
Lease liabilities		52,919	64,905
Deferred government grants		13,751	17,804
		73,670	82,709
Current liabilities			
Trade payables	15	24,101	16,143
Other payables and accruals	16	239,413	157,051
Short-term bank borrowings		273,930	51,900
Derivative financial instruments		1,333	—
Deferred government grants		7,720	5,754
Contract liabilities		37,056	16,916
Lease liabilities		32,251	31,960
		615,804	279,724
Total liabilities		689,474	362,433
Total equity and liabilities		7,718,140	4,354,740

The above condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Changes in Equity

				Equity attributable to equity holders' of the company	Non- controlling interests	Total equity
	Share capital RMB'000 (Note 18)	Other reserves RMB'000 (Note 19)	Accumulated losses RMB'000	RMB'000	RMB'000	RMB'000
(Unaudited)						
Balance at 1 January 2025	237	12,535,678	(8,572,161)	3,963,754	28,553	3,992,307
Profit/(loss) for the period	—	—	82,795	82,795	(7,186)	75,609
Other comprehensive income:						
Currency translation differences	—	(42,340)	—	(42,340)	(151)	(42,491)
Total comprehensive income for the period	—	(42,340)	82,795	40,455	(7,337)	33,118
Transactions with equity holders						
Issuance of ordinary shares, netting of underwriting commissions and other issuance costs	43	2,901,307	—	2,901,350	—	2,901,350
Equity-settled share-based compensation	20	66,019	—	66,019	—	66,019
Proceeds from exercise of share options	20	23,155	—	23,155	—	23,155
Acquisition of a subsidiary	21	—	—	—	12,717	12,717
Total transactions with equity holders	43	2,990,481	—	2,990,524	12,717	3,003,241
Balance at 30 June 2025	280	15,483,819	(8,489,366)	6,994,733	33,933	7,028,666

Condensed Consolidated Statement of Changes in Equity

		Share capital RMB'000 (Note 18)	Other reserves RMB'000 (Note 19)	Accumulated losses RMB'000	Equity attributable to equity holders of the company RMB'000	Non- controlling interests RMB'000	Total equity/ (deficits) RMB'000
	Note						
(Unaudited)							
Balance at 1 January 2024		50	(227,110)	(7,040,349)	(7,267,409)	26,167	(7,241,242)
Loss for the period		—	—	(1,237,016)	(1,237,016)	(534)	(1,237,550)
Other comprehensive income:							
Changes in fair value of convertible redeemable preferred shares due to own credit risk	17	—	(19,774)	—	(19,774)	—	(19,774)
Currency translation differences		—	(22,605)	—	(22,605)	216	(22,389)
Total comprehensive income for the period		—	(42,379)	(1,237,016)	(1,279,395)	(318)	(1,279,713)
Transactions with equity holders							
Conversion of convertible redeemable preferred shares to ordinary shares		173	11,721,245	—	11,721,418	—	11,721,418
Transfer of accumulated changes in fair value due to own credit risk upon derecognition of convertible redeemable preferred shares		—	15,206	(15,206)	—	—	—
Issuance of ordinary shares relating to initial public offering, netting of underwriting commissions and other issuance costs		13	862,136	—	862,149	—	862,149
Equity-settled share-based compensation	20	—	78,922	—	78,922	—	78,922
Total transactions with equity holders		186	12,677,509	(15,206)	12,662,489	—	12,662,489
Balance at 30 June 2024		236	12,408,020	(8,292,571)	4,115,685	25,849	4,141,534

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June

	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cash flows from operating activities		
Net cash used in operating activities	(238,479)	(299,294)
Cash flows from investing activities		
Interest received from term deposits	1,150	41,998
Payments for acquisition of property, plant and equipment	(31,686)	(32,018)
Proceeds from disposals of property, plant and equipment	25	301
Payments for acquisition of intangible assets	(5,162)	(2,166)
Proceeds from disposals of intangible assets	—	232
Payments for acquisition of investments accounted for using equity method	(22,064)	(6,016)
Payments for acquisition of investments in financial assets at fair value through profit or loss	(1,514,344)	(1,464,359)
Proceeds from disposal of financial assets at fair value through profit or loss	933,600	675,081
Proceeds from maturity of derivatives financial instrument	3,823	—
Payments for a business combination for assets	(3,760)	—
Payment for acquisition of a subsidiary, net of cash acquired	(98,816)	—
Placement of term deposits	(1,073,683)	(124,609)
Prepayment for an equity interest investment	(6,085)	—
Proceeds from maturity of term deposits	105,588	955,133
Changes in restricted cash balances	(1,768)	1,809
Proceeds from government grants	1,080	3,265
Net cash (used in)/generated from investing activities	(1,712,102)	48,651
Cash flows from financing activities		
Interest paid for bank borrowings	(1,980)	(773)
Payments of lease liabilities	(14,259)	(39,001)
Net proceeds from issuance of ordinary shares	2,901,350	901,081
Payments of listing expenses	—	(38,151)
Proceeds from exercise of option	3,757	—
Proceeds from short-term bank borrowings	251,930	19,900
Proceeds from long-term bank borrowings	7,000	—
Repayment of short-term bank borrowings	(29,900)	(15,000)
Net cash generated from financing activities	3,117,898	828,056
Net increase in cash and cash equivalents	1,167,317	577,413
Cash and cash equivalents at beginning of the period	1,166,148	710,761
Effects of exchange rate changes on cash and cash equivalents	(21,777)	25,536
Cash and cash equivalents at end of the period	2,311,688	1,313,710

The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Notes to Interim Financial Information

1 GENERAL INFORMATION

XTALPI HOLDINGS LIMITED (the “**Company**”) was incorporated in the Cayman Islands on 28 April 2017 as an exempted company with limited liabilities. The address of its registered office is Maples Corporate Services Limited at PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (collectively, the “**Group**”) are principally engaged in the provision of drug discovery solutions and intelligent robotics solutions.

The Company completed its initial public offering on 13 June 2024 (the “**Listing**”) and the Company’s shares have been listing on the Main Board of The Stock Exchange of Hong Kong Limited.

The condensed consolidated interim financial information is presented in thousands of unit of Renminbi (RMB’000), unless otherwise stated.

This condensed consolidated interim financial information for the six months ended 30 June 2025 is unaudited and has been reviewed by the audit committee and external auditor of the Company. This condensed consolidated interim financial information was approved for issue by the Board of Directors on 27 August 2025.

2 SUMMARY OF ACCOUNTING POLICY INFORMATION

2.1 Basis of preparation

This condensed consolidated interim financial information of the Group for the six months ended 30 June 2025 (the “**Interim Financial Information**”) has been prepared in accordance with International Accounting Standard (“**IAS**”) 34 “Interim Financial Reporting” issued by the International Accounting Standards Board (“**IASB**”).

The Interim Financial Information does not include all the notes of the type normally included in annual financial statements. Accordingly, this Interim Financial Information should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2024, which have been prepared in accordance with IFRS Accounting Standards issued by the IASB.

The preparation of the Interim Financial Information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates. In preparing this Interim Financial Information, the significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty are consistent with those applied in the consolidated financial statements for the year ended 31 December 2024.

2.2 Accounting policy information

(a) *Amendments to standards adopted by the Group*

The following amendments to standards have been adopted by the Group for the financial year beginning on 1 January 2025:

Amendments to IAS 21	Lack of Exchangeability
----------------------	-------------------------

The Company’s directors have performed an assessment on these amendments to standards and have concluded on a preliminary basis that the adoption of these amendments to standards is not expected to have a significant impact on the Group’s financial performance and position.

Notes to Interim Financial Information

2 SUMMARY OF ACCOUNTING POLICY INFORMATION *(Continued)*

2.2 Accounting policy information *(Continued)*

(b) Amendments to standards and new standards not yet adopted

Amendments to standards and new standards that have been issued but are not yet effective and not been early adopted by the Group for the financial year beginning on 1 January 2025 are as follows:

		Effective for accounting periods beginning on or after
Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
IFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
IFRS 19	Subsidiaries without Public Accountability: Disclosures	1 January 2027

The directors have performed assessment on the above new and amendments to standards, and have concluded on a preliminary basis that these new and amendments to standards would not have a significant impact on the Group's consolidated financial statements when they become effective, except for IFRS 18 which will impact the presentation of profit and loss and result in additional disclosure in the consolidated financial statements. The Group is still in the process of evaluating the impact of adoption of IFRS 18.

(c) Accounting policies not included in the Group's annual financial statements for the year ended 31 December 2024

Business combination

The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the:

- the fair values of the assets transferred
- the liabilities incurred to the former owners of the acquired business
- the equity interests issued by the group
- the fair value of any asset or liability resulting from a contingent consideration arrangement, and
- the fair value of any pre-existing equity interest in the subsidiary.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The group recognises any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets.

Acquisition-related costs are expensed as incurred.

Notes to Interim Financial Information

2 SUMMARY OF ACCOUNTING POLICY INFORMATION *(Continued)*

2.2 Accounting policy information *(Continued)*

(c) Accounting policies not included in the Group's annual financial statements for the year ended 31 December 2024 *(Continued)*

Business combination (Continued)

The excess of the:

- the consideration transferred,
- the amount of any non-controlling interest in the acquired entity, and
- the acquisition-date fair value of any previous equity interest in the acquired entity

over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognised directly in profit or loss as a bargain purchase.

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or as a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognised in profit or loss.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognised in profit or loss.

Goodwill

Goodwill arises on the acquisition of subsidiaries represents the excess of the consideration transferred over the Group's interest in net fair value of the net identifiable assets, liabilities and contingent liabilities of the acquiree.

For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units ("**CGUs**"), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level.

Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment. The carrying value of goodwill is compared to the recoverable amount, which is the higher of value in use and the fair value less costs to sell. Any impairment is recognized immediately as an expense and is not subsequently reversed.

2 SUMMARY OF ACCOUNTING POLICY INFORMATION *(Continued)*

2.2 Accounting policy information *(Continued)*

(c) Accounting policies not included in the Group's annual financial statements for the year ended 31 December 2024 *(Continued)*

Inventories

Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realisable value. Cost comprises direct materials, direct labour and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Cost includes the transfer from equity of any gains or losses on qualifying cash flow hedges relating to purchases of raw material, but it excludes borrowing costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

3 FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks, primarily the market risk (including foreign exchange risk, cash flow and fair value interest rate risk and price risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

This condensed consolidated interim financial information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's financial information in the consolidated financial statements for the year ended 31 December 2024.

There have been no changes in the risk management policies since 31 December 2024.

3.2 Fair value estimation

The Group's financial instruments carried at fair value at each reporting date are measured by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorised into three levels within a fair value hierarchy as follows:

- Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.
- Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.
- Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities.

Notes to Interim Financial Information

3 FINANCIAL RISK MANAGEMENT (Continued)

3.2 Fair value estimation (Continued)

The following table presents the Group's financial assets and financial liabilities that are measured at fair value at 30 June 2025 and 31 December 2024:

	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
(Unaudited)				
At 30 June 2025				
Financial assets				
Financial assets at fair value through profit or loss				
— Investment in listed entities	261,330	—	—	261,330
— Investment in the unlisted entities	—	—	381,978	381,978
— Investment in convertible debts	—	—	100,822	100,822
— Investment in private equity funds	—	—	333,563	333,563
— Wealth management products	—	—	1,841,124	1,841,124
	261,330	—	2,657,487	2,918,817
Financial liabilities				
Financial liabilities at fair value through profit or loss				
— Derivative financial instruments	—	1,333	—	1,333
(Audited)				
At 31 December 2024				
Financial assets				
Financial assets at fair value through profit or loss				
— Investment in a listed entity	23,972	—	—	23,972
— Investment in the unlisted entities	—	—	380,131	380,131
— Investment in convertible debts	—	—	69,976	69,976
— Investment in private equity funds	—	—	80,981	80,981
— Wealth management products and funds	—	—	1,786,049	1,786,049
	23,972	—	2,317,137	2,341,109

There were no transfers between level 1, 2 and 3 of fair value hierarchy classifications during the periods ended 30 June 2025 and 2024.

3 FINANCIAL RISK MANAGEMENT *(Continued)*

3.2 Fair value estimation *(Continued)*

(a) Financial instruments in Level 1 and Level 2

The fair value of financial instruments traded in active markets is based on quoted market prices at the reporting date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, price services or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1. Instruments included in level 1 comprised investments in listed instruments classified as financial assets at FVTPL.

The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. Instruments included in level 2 comprised derivative financial instruments.

(b) Financial instruments in Level 3

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

- the use of quoted market prices or dealer quotes for similar instruments,
- discounted cash flow analysis, and
- observable and unobservable inputs, including discount rate, risk-free interest rate, discount for lack of marketability ("**DL**OM"), and expected volatility, etc.

Level 3 instruments of the Group's assets and liabilities include investments in unlisted entities, wealth management products, convertible debt, other financial liabilities and convertible redeemable preferred shares at fair value through profit or loss.

Notes to Interim Financial Information

3 FINANCIAL RISK MANAGEMENT (Continued)

3.2 Fair value estimation (Continued)

(b) Financial instruments in Level 3 (Continued)

The following table presents the changes in level 3 items including investments in unlisted companies, investments in wealth management products and investment in convertible debt at fair value through profit or loss for the periods ended 30 June 2025 and 2024:

	Investments in unlisted companies	Investments in wealth management products	Investment in private equity funds	Investment in convertible debt	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
(Unaudited)					
At 1 January 2025	380,131	1,786,049	80,981	69,976	2,317,137
Additions	56,675	963,518	272,637	28,713	1,321,543
Disposals	—	(920,961)	—	—	(920,961)
Realised gain	—	(12,639)	—	—	(12,639)
Change in fair value	(52,177)	37,011	(18,034)	3,002	(30,198)
Currency translation differences	(2,651)	(11,854)	(2,021)	(869)	(17,395)
At 30 June 2025	381,978	1,841,124	333,563	100,822	2,657,487
(Unaudited)					
At 1 January 2024	316,161	863,368	—	67,595	1,247,124
Additions	5,345	1,443,804	—	20,000	1,469,149
Disposals	(2,847)	(672,234)	—	—	(675,081)
Transfer from a convertible debt to equity	32,553	—	—	(32,553)	—
Change in fair value	799	16,295	—	1,047	18,141
Currency translation differences	1,949	4,059	—	402	6,410
At 30 June 2024	353,960	1,655,292	—	56,491	2,065,743

Notes to Interim Financial Information

3 FINANCIAL RISK MANAGEMENT (Continued)

3.2 Fair value estimation (Continued)

(b) Financial instruments in Level 3 (Continued)

Description	Fair value at		Unobservable inputs	Range of inputs		Relationship of unobservable inputs to fair value
	As at	As at		As at	As at	
	30 June	31 December		30 June	31 December	
	2025	2024		2025	2024	
	RMB'000	RMB'000				
	(Unaudited)	(Audited)		(Unaudited)	(Audited)	
Unlisted preferred shares	41,793	314,487	Risk-free rate	4.39%	1.12%–4.31%	The higher the risk-free rate, the lower the fair value.
			Expected volatility	64%	63%–95%	Depends on rights and restrictions of shares held by the Group.
A series of unlisted preferred shares and ordinary shares	340,185	65,644	Latest transaction price	N/A	N/A	The higher the latest transaction price, the higher the fair value.
A series of convertible bonds	100,822	69,976	Latest transaction price	N/A	N/A	The higher the latest transaction price, the higher the fair value.
Private equity funds	333,563	80,981	N/A	N/A	N/A	N/A
Wealth management products:						
Structured notes	595,946	595,539	N/A	N/A	N/A	N/A
Money funds	1,163,078	1,190,510	N/A	N/A	N/A	N/A
Structured deposits	82,100	—	Expected rate of return	4.43%	N/A	The higher the expected rate of return, the higher the fair value.

Notes:

- (i) Key assumptions used in the valuation of the fair value of investments in unlisted entities include risk-free interest rate and expected volatility. Changes in fair value of investments in unlisted entities were recorded in "Other gains/(losses), net".
- (ii) The Group adopted net assets approach to determine the fair value of structured notes and money funds.

(c) Financial instruments at amortised cost

The carrying amounts of the Group's other financial assets measured at amortised costs, including term deposits, cash and cash equivalents, restricted cash, trade receivables, other receivables and deposits and the Group's financial liabilities, including trade payables, other payables and accruals, approximate their fair values due to their short maturities.

Notes to Interim Financial Information

4 REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue disaggregated by revenue source as follows:

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Drug discovery solutions	435,212	60,850
Intelligent robotics solutions	81,864	41,780
	517,076	102,630
Timing of revenue recognition:		
A point in time	473,275	77,070
Over time	43,801	25,560
	517,076	102,630

Revenue from external customers contributing over 10% to the total revenue of the Group for the six months ended 30 June 2025 and 2024 are as follows:

		For the six months ended 30 June	
		2025	2024
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
Customer A		365,089	N/A*
Customer B		N/A*	19,536

* Less than 10% of the total revenue of the Group in the respective period.

Revenue disaggregated by geography, based on the billing address of the customers is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Mainland China	79,451	47,811
United States	413,311	39,817
Other regions	24,314	15,002
	517,076	102,630

Notes to Interim Financial Information

4 REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)

Segment information:

The chief operating decision-maker (the “**CODM**”) has been identified as the Board, who reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group as a whole. For the purpose of internal reporting and management’s operation review, the CODM considered that the Group’s businesses are operated and managed as one single segment and no separate segment information was presented for the six months ended 30 June 2025 and 2024.

5 EXPENSE BY NATURE

Expenses included in cost of revenue, general and administrative expenses, research and development expenses and selling and marketing expenses are analysed as follows:

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Employee benefit expenses (Note (a))	316,832	315,450
Network and cloud service expenses	13,291	15,797
Short-term rental and utilities	7,116	7,573
Sample material costs	42,048	15,591
Professional service fees	43,912	26,770
Depreciation of property, plant and equipment	38,615	44,263
Impairment provision for property, plant and equipment	28,123	—
Depreciation of right-of-use assets	14,123	38,062
Amortisation of intangible assets	3,305	1,963
Property management fees	8,666	10,694
Listing expenses	—	31,876
Others	28,142	26,781
	544,173	534,820

Note:

(a) Employee benefit expenses

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Wages, salaries and bonuses	211,566	199,495
Pensions costs and housing benefits	37,486	34,142
Share-based compensation expenses (Note 20)	66,019	78,922
Other employee benefits	20,684	20,339
	335,755	332,898
Less: employee benefit expenses capitalised as contract cost	(18,923)	(17,448)
	316,832	315,450

Notes to Interim Financial Information

6 OTHER INCOME

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Government grants	30,646	42,360

The Group received certain financial subsidies from local government authorities with certain specified conditions.

7 OTHER GAINS/(LOSSES), NET

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Net foreign exchange gains/(losses)	3,820	(10,054)
Gains on derivative financial instruments	3,823	3,527
Net fair value changes on financial assets at fair value through profit or loss	34,438	(1,042)
Donations	(5,758)	(108)
Others	1,379	4,916
	37,702	(2,761)

8 INCOME TAX EXPENSE

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current income tax	—	—
Deferred income tax	—	—
	—	—

Income tax expense

The Group's principal applicable taxes and tax rates are as follows:

Cayman Islands

The Company and subsidiaries were incorporated in the Cayman Islands as exempted companies with limited liability under the Companies Act of the Cayman Islands and are not subject to the Cayman Islands income tax pursuant to the current laws of the Cayman Islands.

Hong Kong

The subsidiaries incorporated in Hong Kong are subject to Hong Kong profit tax at a rate of 16.5%. No provision for Hong Kong profits tax has been made as the Group has no estimated assessable profit in Hong Kong.

Notes to Interim Financial Information

8 INCOME TAX EXPENSE (Continued)

Income tax expense (Continued)

United States

The subsidiaries in the United States are subject to Federal Tax at a rate of 21% and State Tax at a rate of 8%.

PRC

The Group's subsidiaries established in the PRC are generally subject to Corporate Income Tax at a rate of 25% on the estimated assessable profit in accordance with relevant PRC income tax laws, subject to preferential tax treatments available to certain qualified enterprises.

Shenzhen Jingtai Technology Co., Ltd., Beijing Jingtai Technology Co., Ltd., Shanghai Zhiyao Technology Co., Ltd., Jingtai Zhiyao Technology (Shanghai) Co., Ltd., and Shanghai Siwei were approved as "High and New Technology Enterprise" and entitled to a preferential income tax rate of 15%. Certain subsidiaries of the Group in the PRC have been granted certain tax concessions for small scale entities by tax authorities in the PRC and enjoy reduced tax rates.

9 EARNINGS/(LOSS) PER SHARE

(a) Basic earnings/(loss) per share

Basic earnings/(loss) per share for the six months ended 30 June 2025 and 2024 are calculated by dividing the profit/(loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the respective period.

	For the six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Profit/(loss) attributable to equity holders of the Company (RMB'000)	82,795	(1,237,016)
Weighted average number of ordinary shares in issue (thousand shares)	3,595,629	729,148
Basic earnings/(loss) per share (expressed in RMB cent per share)	2.30	(169.65)

Notes to Interim Financial Information

9 EARNINGS/(LOSS) PER SHARE *(Continued)*

(b) Diluted earnings/(loss) per share

The share options and awarded shares granted by the Company have potential dilutive effect on the EPS. Diluted EPS is calculated by adjusting the weighted average number of ordinary shares outstanding by the assumption of the conversion of all potential dilutive ordinary shares arising from share options and shares awards granted by the Company (collectively forming the denominator for computing the diluted EPS).

	For the six months ended 30 June 2025 (Unaudited)
Profit attributable to equity holders of the Company (RMB'000)	82,795
Weighted average number of ordinary shares in issue (thousand shares)	3,595,629
Adjustments for share options and share awards (thousand shares)	166,075
Weighted average number of ordinary shares for the calculation of diluted EPS (thousand shares)	3,761,704
Diluted earnings per share (expressed in RMB cent per share)	2.20

Diluted loss per share presented is the same as basic loss per share as the inclusion of the potential ordinary shares in the calculation of dilutive loss per share would be anti-dilutive for the six months ended 30 June 2024.

10 DIVIDENDS

No dividends have been paid or declared by the Company for the six months ended 30 June 2025 and 2024.

Notes to Interim Financial Information

11 PROPERTY, PLANT AND EQUIPMENT, RIGHT-OF-USE ASSETS AND INTANGIBLE ASSETS

	Property, plant and equipment RMB'000	Right-of-use assets RMB'000	Intangible assets RMB'000
(Unaudited)			
Opening net book amount as at 1 January 2025	320,397	90,920	7,743
Additions	39,743	988	5,421
Business combination	538	—	221,004
Disposals	(2,105)	—	—
Impairment provision	(28,123)	—	—
Depreciation and amortisation charge	(38,615)	(14,123)	(3,305)
Currency translation adjustment	723	(75)	(1)
Closing net book amount as at 30 June 2025	292,558	77,710	230,862
At 30 June 2025			
Cost	569,385	168,338	245,212
Accumulated depreciation and impairment	(276,827)	(90,628)	(14,350)
Net book amount	292,558	77,710	230,862
(Unaudited)			
Opening net book amount as at 1 January 2024	369,887	189,250	7,869
Additions	32,018	12,601	2,166
Disposals	(301)	(68,776)	(232)
Depreciation and amortisation charge	(44,263)	(38,062)	(1,963)
Currency translation adjustment	15	—	9
Closing net book amount as at 30 June 2024	357,356	95,013	7,849
At 30 June 2024			
Cost	532,697	171,729	22,008
Accumulated depreciation	(175,341)	(76,716)	(14,159)
Net book amount	357,356	95,013	7,849

Notes to Interim Financial Information

12 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Non-current:		
Investments in listed entities	261,330	23,972
Investments in the unlisted entities <i>(Note)</i>	381,978	380,131
Investments in convertible debts <i>(Note)</i>	100,822	69,976
Investments in private equity funds <i>(Note)</i>	333,563	80,981
	1,077,693	555,060
Current:		
Wealth management products <i>(Note)</i>	1,841,124	1,786,049

Note:

Movements in these financial assets measured at fair value through profit or loss for the six months ended 30 June 2025 are disclosed in Note 3.2.

13 TRADE AND NOTE RECEIVABLES

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Trade receivables	496,513	94,300
Less: credit loss allowance	(2,725)	(2,850)
	493,788	91,450
Note receivables	3,219	7,296
	497,007	98,746

Notes to Interim Financial Information

13 TRADE AND NOTE RECEIVABLES *(Continued)*

The credit period granted to the Group's customers is usually 30–60 days. As at 30 June 2025 and 31 December 2024, the aging analysis of trade receivables based on invoice dates is as follows:

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
0 to 90 days	451,510	82,298
91 to 180 days	11,196	2,397
181 to 365 days	28,239	2,314
Over 1 year	5,568	7,291
	496,513	94,300

Movements on the Group's credit loss allowance for trade receivables are as follows:

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
At beginning of the period	2,850	1,820
Net provision of impairment loss during the period	5,160	268
Written off	(5,285)	—
At end of the period	2,725	2,088

Notes to Interim Financial Information

14 PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Non-current		
Prepayment for equipment	19,004	18,251
Current		
Prepayments	30,243	24,511
Deposits	10,600	10,613
Value-added tax recoverables	20,470	15,824
Receivables from employee share options exercised	31,572	26,462
Loan to a third party and interest receivable	5,210	5,209
Loan to an associate and interest receivable	3,132	1,530
Others	2,958	1,211
	104,185	85,360
Less: loss allowance	(3,657)	(228)
	100,528	85,132

The carrying amounts of deposits and other receivables approximate their fair values and are mainly dominated in RMB. The recoverability was assessed with reference to the credit status of the recipients and, as there is no significant increase in credit risk since initial recognition, the 12-month expected credit loss is considered minimal.

15 TRADE PAYABLES

Trade payables were mainly denominated in RMB as at 30 June 2025 and 31 December 2024. The credit periods granted by suppliers generally range from 30 to 180 days. The aging analysis of trade payables, based on invoice date, is as follows:

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
0 to 90 days	14,994	11,761
90 to 180 days	9,107	4,382
	24,101	16,143

Notes to Interim Financial Information

16 OTHER PAYABLES AND ACCRUALS

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Accrued salaries and staff benefits	61,136	78,360
Accrual for acquiring property, plant, and equipment	6,242	13,115
Withholding personal income tax for employees	3,619	9,799
Investment payables	137,653	24,885
Other payables to employees	10,882	14,300
Professional service fee payable	4,308	—
Other tax payables	2,894	925
Rental payables	3,628	2,875
Others	9,051	12,792
	239,413	157,051

The carrying amounts of other payables and accruals of the Group are mainly denominated in RMB.

17 CONVERTIBLE REDEEMABLE PREFERRED SHARES

Historically, the Company has completed several rounds of financing by issuing convertible redeemable preferred shares to investors. In June 2024, the Company completed IPO on the Main Board of The Stock Exchange of Hong Kong Limited. Upon listing, all of the preferred shares were automatically converted into ordinary shares, and the related liabilities were derecognized.

The movements of the CRPS during the period ended 30 June 2024 are set out as below:

	For the six months ended 30 June 2024 RMB'000 (Unaudited)
At 1 January 2024	10,780,342
Change in fair value through profit or loss	875,356
Change in fair value through other comprehensive income	19,774
Currency translation differences	45,946
Conversion of CRPS to ordinary shares	(11,721,418)
At 30 June 2024	—

Notes to Interim Financial Information

18 SHARE CAPITAL

Authorised:

	Class A ordinary shares (At par value of US\$0.00001)	Class B ordinary share (At par value of US\$0.00001)	Ordinary shares (At par value of US\$0.00001) (Number of shares)	Preferred shares (At par value of US\$0.00001)	Total
(Unaudited)					
At 1 January 2024	2,132,966,842	429,653,340	—	2,437,379,818	5,000,000,000
Creation of addition of Class A ordinary shares	95,000,000,000	—	—	—	95,000,000,000
Conversion of preferred shares into Class A ordinary shares	2,437,379,818	—	—	(2,437,379,818)	—
Re-designation of to ordinary shares	(99,570,346,660)	(429,653,340)	100,000,000,000	—	—
At 30 June 2024, 1 January 2025 and 30 June 2025	—	—	100,000,000,000	—	100,000,000,000

Pursuant to the Articles and the Pre-IPO Shareholders' Agreement, all the preferred shares shall be automatically and immediately converted into Class A ordinary shares upon completion of an initial public offering of the Company. The preferred shares will be converted into Class A ordinary shares on a one-to-one ratio and subject to customary adjustments.

Upon the completion of the initial public offering by the Company on 13 June 2024, all the preferred shares were automatically converted into Class A ordinary shares. Upon the conversion of all the issued and outstanding preferred shares into Class A ordinary shares, the weighted voting rights structure also ceased as all Class A and Class B ordinary shares entitle the holder to exercise one vote on all matters subject to the vote general meetings of the Company. Immediate following the above conversion all Class A and Class B ordinary shares are re-designated and reclassified as ordinary shares with par value of US\$0.00001 each.

Notes to Interim Financial Information

18 SHARE CAPITAL (Continued)

Issued and fully paid:

	Class A ordinary shares	Class B ordinary shares	Number of ordinary shares	Total	Nominal value of ordinary shares (At par value of US\$0.00001) RMB'000
		(Number of shares)			
(Unaudited)					
At 1 January 2025	—	—	3,413,523,761	3,413,523,761	237
Issuance of ordinary shares (note (i))	—	—	606,288,000	606,288,000	43
At 30 June 2025	—	—	4,019,811,761	4,019,811,761	280
At 1 January 2024	352,366,603	429,653,340	—	782,019,943	50
Conversion of convertible redeemable preferred shares into Class A ordinary shares	2,437,379,818	—	—	2,437,379,818	173
Re-designation of to ordinary shares	(2,789,746,421)	(429,653,340)	3,219,399,761	—	—
Issuance of ordinary shares (note (ii))	—	—	187,373,000	187,373,000	13
At 30 June 2024	—	—	3,406,772,761	3,406,772,761	236

Note:

- (i) On 24 January 2025 and 25 February 2025, the Group successfully completed placings of 264,000,000 and 342,288,000 new shares at the prices of HK\$4.28 and HK\$6.10 per share, respectively.
- (ii) On 13 June 2024, upon the Listing on the Main Board of the Stock Exchange, the Company issued 187,373,000 new ordinary shares at par value of US\$0.00001 per share for cash consideration of HK\$5.28 each.

Notes to Interim Financial Information

19 OTHER RESERVES

	Share premium RMB'000	Treasury shares RMB'000	Exchange reserves RMB'000	Share-based payment reserves RMB'000	Others RMB'000	Total RMB'000
(Unaudited)						
As at 1 January 2025	12,636,242	(19)	(447,452)	289,634	57,273	12,535,678
Issuance of ordinary shares	2,901,307	—	—	—	—	2,901,307
Equity-settled share-based compensation	—	—	—	66,019	—	66,019
Exercise of share options	26,376	2	—	(3,223)	—	23,155
Currency translation difference	—	—	(42,340)	—	—	(42,340)
As at 30 June 2025	15,563,925	(17)	(489,792)	352,430	57,273	15,483,819
(Unaudited)						
As at 1 January 2024	4,591	(19)	(447,815)	154,292	61,841	(227,110)
Conversion of convertible redeemable preferred shares into Class A ordinary shares	11,721,245	—	—	—	—	11,721,245
Transfer of accumulated changes in fair value due to own credit risk upon derecognition of convertible redeemable preferred shares	—	—	—	—	15,206	15,206
Fair value change on convertible redeemable preferred shares due to own credit risk	—	—	—	—	(19,774)	(19,774)
Issuance of ordinary shares relating to initial public offering, netting of underwriting commissions and other issuance costs	862,136	—	—	—	—	862,136
Equity-settled share-based compensation	—	—	—	78,922	—	78,922
Currency translation difference	—	—	(22,605)	—	—	(22,605)
As at 30 June 2024	12,587,972	(19)	(470,420)	233,214	57,273	12,408,020

Notes to Interim Financial Information

20 SHARE-BASED PAYMENTS

During the six months ended 30 June 2025 and 2024, the Group has a Pre-IPO Share Incentive Plan and a Post-IPO RSU Scheme in place under which options and RSUs have been granted.

(a) Pre-IPO Share Incentive Plan

During the year ended 31 December 2021, the board of directors of the Company approved the establishment of the Omnibus Incentive Plan ("**Pre-IPO Share Incentive Plan**") with the purpose of motivating, attracting and retaining those individuals for outstanding performance to generate superior returns to the shareholders of the Group. The Pre-IPO Share Incentive Plan is valid and effective for 10 years from the date of the approval of the board of directors. The maximum aggregated number of shares which may be issued pursuant to the Pre-IPO Incentive Plan is 298,041,143 ordinary shares.

According to the Pre-IPO Share Incentive Plan, 298,041,143 ordinary shares have been reserved under QuantumPharm Roc Holdings Limited, the shareholding platform to be issued to any qualified participants.

The exercise price of options is based on a fixed price in the agreement with employees. The term of the Option shall expire at close of the principal stock market or exchange on which the Shares are quoted or traded on the tenth (10th) anniversary of the Grant Date, unless terminated earlier in accordance herewith. In no event may any portion of the Option be exercised after it has expire.

Set out below are summaries of options granted under the plan:

	Number of options 2021 Share Option Plan	Weighted average exercise price per share option US\$
(Unaudited)		
Outstanding as at 1 January 2025	288,016,643	0.17
Forfeited during the period	(2,687,500)	0.39
Exercised during the period	(26,150,500)	0.12
Outstanding as at 30 June 2025	259,178,643	0.17
Vested and exercisable at 30 June 2025	156,912,131	0.16
(Unaudited)		
Outstanding as at 1 January 2024	297,555,144	0.16
Granted during the period	14,527,004	0.25
Forfeited during the period	(14,531,004)	0.29
Outstanding as at 30 June 2024	297,551,144	0.16
Vested and exercisable at 30 June 2024	180,616,400	—

Notes to Interim Financial Information

20 SHARE-BASED PAYMENTS (Continued)

(a) Pre-IPO Share Incentive Plan (Continued)

Share options under Pre-IPO Share Incentive Plan outstanding at the end of the period have the following expiry date and exercise prices:

Grant date	Expiry date	Exercise price US\$	Vesting year	As at 30 June 2025 (Unaudited)	As at 30 June 2024 (Unaudited)
1 October 2015	1 October 2025	0.00001	4 years from grant date	22,837,200	22,837,200
1 October 2015	15 July 2031	0.00080	4 years from grant date	10,000,000	10,000,000
26 November 2015	26 November 2025	0.00032	4 years from grant date	800,000	1,550,000
1 March 2016	1 March 2026	0.00032	4 years from grant date	500,000	1,500,000
1 March 2016	1 March 2026	0.00150	4 years from grant date	8,000,000	8,000,000
1 March 2016	1 March 2026	0.00284	4 years from grant date	—	200,000
1 February 2017	1 February 2027	0.00150	4 years from grant date	7,000,000	7,000,000
1 February 2017	1 February 2027	0.00284	4 years from grant date	706,000	1,190,000
1 February 2017	1 February 2027	0.01733	4 years from grant date	—	80,000
1 March 2017	1 March 2027	0.00150	4 years from grant date	3,000,000	5,000,000
1 June 2017	1 June 2027	0.00284	4 years from grant date	—	2,500,000
16 September 2017	16 September 2027	0.00284	4 years from grant date	2,327,000	3,025,000
16 September 2017	16 September 2027	0.02160	4 years from grant date	—	700,000
1 August 2018	1 August 2028	0.00284	4 years from grant date	2,700,000	3,000,000
1 August 2018	1 August 2028	0.00710	4 years from grant date	1,070,000	2,700,000
1 August 2018	1 August 2028	0.07352	4 years from grant date	570,000	670,000
1 March 2019	1 March 2029	0.00710	4 years from grant date	1,291,000	2,530,000
1 March 2019	1 March 2029	0.09421	4 years from grant date	2,840,000	4,224,500
3 September 2019	3 September 2029	0.00284	4 years from grant date	1,000,000	1,000,000
3 September 2019	3 September 2029	0.02872	4 years from grant date	605,000	1,790,000
3 September 2019	3 September 2029	0.26309	4 years from grant date	532,149	532,149
1 March 2020	1 March 2030	0.06705	4 years from grant date	680,000	1,130,000
1 March 2020	1 March 2030	0.17441	4 years from grant date	800,000	800,000
28 September 2020	28 September 2030	0.18792	4 years from grant date	320,000	560,000
1 January 2021	1 January 2031	0.00284	4 years from grant date	2,500,000	2,600,000
1 January 2021	1 January 2031	0.18792	4 years from grant date	—	30,000
1 January 2021	1 January 2031	0.18792	Fully vested upon listing	—	12,000,000
15 April 2021	15 April 2031	0.00284	4 years from grant date	2,665,925	2,665,925
15 April 2021	15 April 2031	0.18792	4 years from grant date	413,000	1,340,000
15 April 2021	15 April 2031	0.18792	Fully vested upon listing	36,752,018	36,752,019
15 April 2021	15 April 2031	0.18792	Fully vested upon listing	38,183,588	38,183,588
15 April 2021	15 April 2031	0.33876	4 years from grant date	1,750,000	3,400,000
1 October 2021	1 October 2031	0.18792	4 years from grant date	120,000	350,000
26 November 2021	26 November 2031	0.30565	4 years from grant date	12,500	50,000
1 January 2022	1 January 2032	0.30565	4 years from grant date	—	2,100,000
11 January 2022	11 January 2032	0.18792	4 years from grant date	300,000	300,000
31 March 2022	31 March 2032	0.18792	4 years from grant date	15,000	50,000
31 March 2022	31 March 2032	0.30565	4 years from grant date	90,000	90,000
30 June 2022	30 June 2032	0.30565	4 years from grant date	105,000	140,000
30 June 2022	30 June 2032	0.52234	4 years from grant date	40,000	80,000
30 September 2022	30 September 2032	0.30565	4 years from grant date	1,135,000	1,400,000

Notes to Interim Financial Information

20 SHARE-BASED PAYMENTS (Continued)

(a) Pre-IPO Share Incentive Plan (Continued)

Grant date	Expiry date	Exercise price US\$	Vesting year	As at 30 June 2025 (Unaudited)	As at 30 June 2024 (Unaudited)
31 December 2022	31 December 2032	0.30565	4 years from grant date	—	300,000
31 December 2022	31 December 2032	0.46200	4 years from grant date	400,000	800,000
31 March 2023	31 March 2033	0.30565	4 years from grant date	10,000	340,000
30 June 2023	30 June 2033	0.30565	4 years from grant date	270,000	270,000
30 September 2023	30 September 2033	0.30565	4 years from grant date	2,111,000	2,850,000
30 September 2023	30 September 2033	0.18792	4 years from grant date	7,358,000	8,630,000
30 September 2023	30 September 2033	0.18792	2 years from grant date	80,000	80,000
30 September 2023	30 September 2033	0.48000	4 years from grant date	1,190,000	1,780,000
30 September 2023	30 September 2033	0.48000	3 years from grant date	180,000	180,000
24 November 2023	24 November 2033	0.48000	4 years from grant date	50,000	100,000
24 November 2023	24 November 2033	0.24678	4 years from grant date	83,703,759	83,703,759
1 March 2024	1 March 2034	0.18792	4 years from grant date	10,064,004	10,517,004
1 March 2024	1 March 2034	0.18792	3 years from grant date	751,500	920,000
1 March 2024	1 March 2034	0.18792	2 years from grant date	300,000	300,000
1 March 2024	1 March 2034	0.30565	4 years from grant date	150,000	150,000
1 March 2024	1 March 2034	0.52700	4 years from grant date	900,000	2,580,000
				259,178,643	297,551,144
Weighted average remaining contractual life of options outstanding at end of period				5.70	6.59

The options may exercise of any time after the IPO of the Company provided the options have vested and subject to the term of the share option agreement.

The Group estimate the expected forfeiture rate at the end of vesting periods (“**Forfeiture Rate**”) of the share options granted in order to determine the amount of share-based payment expenses charged to profit or loss.

The directors of the Company have used the binomial model to determine the fair value of the options as at the respective grant dates, which is to be expensed over the relevant vesting period.

Notes to Interim Financial Information

20 SHARE-BASED PAYMENTS *(Continued)*

(a) Pre-IPO Share Incentive Plan *(Continued)*

Other than the exercise price mentioned above, significant judgment on parameter such as risk free rate, dividend yield and expected volatility, are required to be made by the directors in applying the binomial model, which are summarised as below:

	For the six months ended 30 June 2024 (Unaudited)
Fair value per share (in US\$)	0.33–0.5
Exercise price (in US\$)	0.19–0.59
Risk-free interest rate	4.18%
Expected Life	10 years
Expected volatility	79.23%
Dividend yield	—

(b) Post-IPO RSU Scheme

On 28 May 2024, the board of directors of the Company approved the establishment of the Post-IPO RSU Scheme. The maximum aggregate number of shares permitted to be awarded under the share award scheme is limited to 204,406,365 new shares.

During the year ended 31 December 2024, the Company granted certain RSUs to eligible grantees, without consideration following the terms of the Post-IPO RSU Scheme, subject to the satisfaction of certain performance requirements as set out in the awards agreements and shall vest from grant date over four years.

Movement in the number of RSUs granted to eligible grantees of the Group for the period ended 30 June 2025 are as follows:

	Number of RSUs	Weighted average grant date fair value HK\$
Outstanding as at 1 January 2025 and 30 June 2025	1,800,000	5.55

The fair value of the RSUs was calculated based on the market price of the Company's shares on the date of grant.

(c) Expenses arising from share-based payment transactions

For the six months ended 30 June 2025 and 2024, share-based payment expenses of RMB66,019,000 and RMB78,922,000 were recognised respectively.

21 BUSINESS COMBINATIONS

(a) Summary of acquisition

On 10 May 2025, XtalPi and the Shanghai Siwei entered into the Agreement, pursuant to which XtalPi agreed to purchase the 90% equity interest in Shanghai Siwei at a consideration of RMB250 million, to be fully settled by cash. Upon Completion, XtalPi acquired 90% equity interest in Shanghai Siwei. Shanghai Siwei became an indirect non-wholly owned subsidiary of the Company.

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

	RMB'000
Total purchase consideration and cash paid	250,000

The assets and liabilities recognised as a result of the acquisition are as follows:

	RMB'000
Cash and cash equivalents	26,184
Property, plant and equipment	538
Prepayment	275
Inventories	824
Receivables	18,824
Investments	233
Deferred tax assets	1,339
Payables	(5,376)
Contract liabilities	(1,128)
Intangible assets other than goodwill	85,454
	127,167
Less: non-controlling interest	(12,717)
Add: goodwill	135,550
	250,000

Goodwill is attributable to Shanghai Siwei's strong position and profitability in providing remote diagnostic service solutions, ECG, remote ultrasound imaging diagnosis, AI remote diagnostic innovation business and cost synergies expected to arise as the result of the acquisition. Goodwill has been allocated to the Shanghai Siwei. Goodwill is not tax deductible.

(i) Acquired receivables

The fair value of trade and other receivables is RMB18,824,000 and includes trade receivables with a fair value of RMB18,441,000.

(ii) Revenue and profit contribution

The acquired business contributed revenues of RMB2,925,000 and net profit of RMB1,024,000 to the group for the period from 16 May 2025 to 30 June 2025.

Notes to Interim Financial Information

22 RELATED-PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Parties are also considered to be related if they are subjected to common control. Members of key management and their close family members of the Group are also considered as related parties.

The following significant transactions were carried out between the Group and its related parties during the period ended 30 June 2025. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties.

(a) Transactions with related parties

	For the six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenue from services provided for associates	—	312

Revenue from services provided and services purchased were based on terms mutually agreed with related parties and in the ordinary course of business.

(b) Balances with related parties

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Trade nature:		
Amounts receivable from an associate (note (i))	210	210
Contract liability due to an associate (note (i))	2,863	—
Non-trade nature:		
Investment payable due to an associate (note (i))	4,886	4,886
Loan to an associate and interest receivables (note (ii))	3,132	1,530

Note:

- (i) The balance with related parties are unsecured, interest-free and are repayable on demand.
- (ii) The loan to an associate is secured, interest-bearing and is repayment on demand. During the period ended 30 June 2025, the Group has made a full provision for impairment of the loan to an associate and interest receivables amounted to RMB3,132,000.

Notes to Interim Financial Information

22 RELATED-PARTY TRANSACTIONS *(Continued)*

(c) Key management personnel compensation

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Wages, salaries and bonuses	30,708	24,839
Pensions costs, housing benefits and other employee benefits	1,551	2,758
Share-based compensation expenses	54,942	76,531
	87,201	104,128

23 CONTINGENT LIABILITIES

As at 30 June 2025, there were no material contingent liabilities to the Group.

24 EVENTS OCCURRING AFTER THE REPORTING PERIOD

Subsequent to 30 June 2025 and up to the date of this report, the Group has entered into several equity related investments with several entities and subscribed several wealth management products with total consideration of approximately RMB122.5 million and RMB316.4 million, respectively.

Definitions

In this interim report unless the context otherwise requires, the following terms shall have the meaning set out below.

“Audit Committee”	the audit committee of our Board
“Board”	the board of Directors
“BVI”	the British Virgin Islands
“CCASS”	the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited
“China” or “PRC”	the People’s Republic of China, but for the purpose of this interim report and for geographical reference only and except where the context requires otherwise, references in this report to “China” and the “PRC” do not apply to Hong Kong, the Macao Special Administrative Region and Taiwan
“Company”	XtalPi Holdings Limited 晶泰控股有限公司, an exempted company incorporated in the Cayman Islands with limited liability on 28 April 2017, the Shares of which are listed on the Stock Exchange (stock code: 2228)
“Corporate Governance Code”	the Corporate Governance Code set out in Appendix C1 to the Listing Rules
“Crete Helix”	Crete Helix Ltd., a company incorporated in the BVI with limited liability on 25 May 2021, which is owned as to 1% by Jian Guo Pai and 99% by MH International Holdings
“CRPS”	convertible redeemable preferred shares
“Director(s)”	the director(s) of our Company
“FVTPL”	fair value through profit or loss
“Global Offering”	has the same meaning as defined in the Prospectus
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“IFRS”	IFRS Accounting Standards, which include standards, amendments and interpretations promulgated by the International Accounting Standards Board and the International Accounting Standards and Interpretation issued by the International Accounting Standards Committee
“Listing”	the listing of the Shares on the Stock Exchange
“Listing Date”	13 June 2024, being the date on which the Shares are listed on the Stock Exchange

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“LPHappy Family Trust”	the discretionary trust established on 28 June 2021 by Dr. Lai Lipeng as the settlor with TMF (Cayman) Ltd. as the trustee
“LPHappy Holding”	LPHappy Holding Limited, a company incorporated in the BVI with limited liability on 28 June 2021, which is a holding vehicle wholly owned by TMF (Cayman) Ltd., the trustee of the LPHappy Family Trust
“MH Fund Trust”	the discretionary trust established on 29 June 2021 by Dr. Ma Jian as the settlor with TMF (Cayman) Ltd. as the trustee
“MH International Holdings”	MH International Holdings Limited, a company incorporated in the BVI with limited liability on 28 June 2021, which is a holding vehicle wholly owned by TMF (Cayman) Ltd., a trustee of MH Fund Trust
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
“Ordinary Share(s)” or “Share(s)”	the ordinary share(s) of US\$0.00001 each (or such par value as adjusted from time to time) in the share capital of the Company
“Post-IPO RSU Scheme”	the restricted share unit scheme conditionally adopted by the Shareholders on 28 May 2024 which came into effect upon Listing
“Post-IPO Share Option Scheme”	the share option scheme conditionally adopted by the Shareholders on 28 May 2024 which came into effect upon Listing
“Pre-IPO ESOP”	the QuantumPharm Inc. 2021 Omnibus Incentive Plan as adopted by the Shareholders on 14 July 2021 and amended on 5 August 2021
“Prospectus”	the prospectus of the Company dated 4 June 2024
“QuantumPharm Employee Benefit Trust”	the discretionary trust established on 28 June 2021 with TMF Trust (HK) Limited as trustee and 13 employees and ex-employees of our Group as beneficiaries for the purpose of managing and administering the options granted to them under the Pre-IPO ESOP
“QuantumPharm Employee Holdings”	QuantumPharm Employee Holdings, a company incorporated in the BVI with limited liability on 25 June 2021, which is a holding vehicle wholly owned by TMF Trust (HK) Limited as trustee of the QuantumPharm Employee Benefit Trust
“QuantumPharm Holdings”	QuantumPharm Holdings Limited, a company incorporated in the BVI with limited liability on 25 April 2017, which is owned as to 1% by SSBL Holdings and 99% by WSH Family Holdings

Definitions

“QuantumPharm Roc”	QuantumPharm Roc Holdings Limited, a company incorporated in the BVI with limited liability on 12 April 2019, which is wholly owned by QuantumPharm Holdings
“Renminbi” or “RMB”	the lawful currency of the PRC
“Reporting Period”	the six months ended 30 June 2025
“RSU(s)”	restricted share unit(s)
“Scheme Limit”	the maximum number of Shares in respect of which options and awards may be granted under the share schemes of the Company
“Sevening B Holdings”	Sevening B Holdings Limited, a company incorporated in the BVI with limited liability on 20 April 2017, which is wholly owned by Dr. Lai Lipeng
“SeveningBAlpha”	SeveningBAlpha Limited, a company incorporated in the BVI with limited liability on 20 May 2021, which is owned as to 1% by Sevening B Holdings and 99% by LPHappy Holding
“SFO”	the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong)
“Shareholder(s)”	holder(s) of the Share(s)
“SSBL Holdings”	SSBL Holdings Limited, a company incorporated in the BVI with limited liability on 20 April 2017, which is wholly owned by Dr. Wen Shuhao
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“treasury shares”	Shares repurchased and held by the Company in treasury (which include Shares repurchased by the Company and held or deposited in CCASS for sale on the Stock Exchange) from time to time
“U.S.” or “United States”	the United States of America, its territories and possessions, any State of the United States, and the District of Columbia
“US\$”	United States dollars, the lawful currency of the United States
“WSH Family Holdings”	WSH Family Holdings Limited, a company incorporated in the BVI with limited liability on 27 August 2021, which is a holding vehicle wholly owned by TMF (Cayman) Ltd., a trustee of the WSH Family Trust
“WSH Family Trust”	the discretionary trust established by Dr. Wen Shuhao as the settlor with TMF (Cayman) Ltd. as the trustee
“%”	per cent